<SEC-DOCUMENT>0001683168-25-006788.txt : 20250909
<SEC-HEADER>0001683168-25-006788.hdr.sgml : 20250909
<ACCEPTANCE-DATETIME>20250909161042
ACCESSION NUMBER:		0001683168-25-006788
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20250904
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250909
DATE AS OF CHANGE:		20250909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37487
		FILM NUMBER:		251303280

	BUSINESS ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		619-941-0360

	MAIL ADDRESS:	
		STREET 1:		11555 SORRENTO VALLEY ROAD, SUITE 203
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aemd_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:AEMD="http://aethlonmedical.com/20250904">
<head>
     <title>AETHLON MEDICAL, INC. 8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_AEMD_aethlonmedical.com_20250904 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250904_20250904 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0000882291 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000004" name="dei:EntityCentralIndexKey">0000882291</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="aemd-20250904.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000882291</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-04</xbrli:startDate>
        <xbrli:endDate>2025-09-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 12pt"><b>FORM <span id="xdx_900_edei--DocumentType_c20250904__20250904_zFL5bhKG6vTk"><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b><span id="xdx_909_edei--DocumentPeriodEndDate_c20250904__20250904_zO1TKGp404Gf"><ix:nonNumeric contextRef="AsOf2025-09-04" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September 4, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_908_edei--EntityRegistrantName_c20250904__20250904_z9IU7EQ7hm6l" style="font-size: 18pt"><b><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000011" name="dei:EntityRegistrantName">Aethlon
Medical, Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 39%; font-size: 10pt; text-align: center"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20250904__20250904_zIzhfbfstjg9"><ix:nonNumeric contextRef="AsOf2025-09-04" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 22%; font-size: 10pt; text-align: center"><b><span id="xdx_90E_edei--EntityFileNumber_c20250904__20250904_z7AOOsRNQiS"><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000013" name="dei:EntityFileNumber">001-37487</ix:nonNumeric></span></b></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 39%; font-size: 10pt; text-align: center"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20250904__20250904_zjz5ACjE7onl"><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000014" name="dei:EntityTaxIdentificationNumber">13-3632859</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of
    incorporation)</p></td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</p></td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(IRS Employer Identification No.)</p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 50%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20250904__20250904_zlgTtC88oe1e"><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000015" name="dei:EntityAddressAddressLine1">11555
    Sorrento Valley Road</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20250904__20250904_zbnfAgPIrYS5"><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite
    203</ix:nonNumeric></span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90F_edei--EntityAddressCityOrTown_c20250904__20250904_z0tR7JaLmba2"><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000017" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20250904__20250904_zbSjk5pYEnYf"><ix:nonNumeric contextRef="AsOf2025-09-04" format="ixt-sec:stateprovnameen" id="Fact000018" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span></b></p></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center; width: 50%"><b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20250904__20250904_zMbro8sHqKXc"><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000019" name="dei:EntityAddressPostalZipCode">92121</ix:nonNumeric></span></b></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">(Address of principal executive offices)</td>
    <td style="vertical-align: top; text-align: center">(Zip Code)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_90E_edei--CityAreaCode_c20250904__20250904_z1mB9RNXkROa"><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000020" name="dei:CityAreaCode">619</ix:nonNumeric></span>)</b><b> <span id="xdx_90B_edei--LocalPhoneNumber_c20250904__20250904_zzg33Bw0jb7k"><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000021" name="dei:LocalPhoneNumber">941-0360</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--WrittenCommunications_c20250904__20250904_zmdqMQDQjS7b"><ix:nonNumeric contextRef="AsOf2025-09-04" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--SolicitingMaterial_c20250904__20250904_zjvJnSe9rdJ4"><ix:nonNumeric contextRef="AsOf2025-09-04" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--PreCommencementTenderOffer_c20250904__20250904_zMajKAueHmB"><ix:nonNumeric contextRef="AsOf2025-09-04" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 4%"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20250904__20250904_z4YBJsN09CJk"><ix:nonNumeric contextRef="AsOf2025-09-04" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; white-space: nowrap; width: 37%; text-align: center">Title of each class</td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 24%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Trading Symbol(s)</p></td>
    <td style="padding-bottom: 1pt; width: 1%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; width: 37%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Name of each exchange on which registered</p></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_900_edei--Security12bTitle_c20250904__20250904_z5hCgQFXP9Nb"><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000026" name="dei:Security12bTitle">Common Stock, $0.001 par value per share</ix:nonNumeric></span></b></p></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><b><span id="xdx_904_edei--TradingSymbol_c20250904__20250904_zzcHnlAh0nK2"><ix:nonNumeric contextRef="AsOf2025-09-04" id="Fact000027" name="dei:TradingSymbol">AEMD</ix:nonNumeric></span></b></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><b>The <span id="xdx_906_edei--SecurityExchangeName_c20250904__20250904_zJL8Uj0QqQa2"><ix:nonNumeric contextRef="AsOf2025-09-04" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20250904__20250904_z4jn0Hryy8Cb"><ix:nonNumeric contextRef="AsOf2025-09-04" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo; Options: Hidden -->&#160;<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>Item&#8201;1.01 Entry into a Material Definitive
Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 4, 2025,
Aethlon Medical, Inc., a Nevada corporation (the &#8220;Company&#8221;), entered into a Securities Purchase Agreement (the &#8220;Purchase
Agreement&#8221;) with certain investors (the &#8220;Investors&#8221;), pursuant to which the Company agreed to sell, issue, and deliver,
in a registered public offering (the &#8220;Offering&#8221;) (i) 4,047,780 shares (&#8220;Shares&#8221;) of common stock, par value $0.001
per share (the &#8220;Common Stock&#8221;), (ii) 5,000,000 warrants to purchase up to 5,000,000 shares of Common Stock (the &#8220;Common
Warrants&#8221;), (iii) 952,220 Pre-Funded Warrants to purchase up to 952,220 shares of Common Stock (the &#8220;Pre-Funded Warrants&#8221;),
(iv) 200,000 warrants to purchase up to 200,000 shares of Common Stock (the &#8220;Placement Agent Warrants&#8221;, and together with
the Pre-Funded Warrants and Common Warrants, the &#8220;Warrants&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Under the terms of the
Purchase Agreement, the Company agreed to sell one share of its Common Stock or a Pre-Funded Warrant in lieu thereof, together with one
Common Warrant (collectively, a &#8220;Common Unit&#8221;) sold in the Offering at a combined public offering price of $0.90 per Common
Unit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Common Warrants are
exercisable immediately upon issuance and have an exercise price of $0.90 per share, subject to adjustment as set forth therein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Offering closed on
September 5, 2025. The securities were registered pursuant to the registration statement, on Form S-1 (File No. 333-289745), which was
initially filed with the Securities and Exchange Commission (the &#8220;Commission&#8221;) on August 20, 2025, and amended on August 29,
2025, which the Commission declared effective on September 4, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Maxim Group LLC acted
as the exclusive placement agent (the &#8220;Placement Agent&#8221;) in connection with the Offering. On September 4, 2025, the Company
and the Placement Agent entered into a Placement Agency Agreement (the &#8220;Placement Agency Agreement&#8221;), pursuant to which, as
compensation for services rendered by the Placement Agent in connection with the Offering, the Company agreed to pay the Placement Agent
an aggregate cash fee of 6.25% of the aggregate gross proceeds of the Offering (amounting to $281,250) at closing, as well as $100,000
for the reimbursement of certain of the Placement Agent&#8217;s expenses. Additionally, the Company issued to the Placement Agent, as
part of the Placement Agent&#8217;s compensation, 200,000 warrants to purchase up to an aggregate of 200,000 shares of Common Stock, equal
to 4.0% of the aggregate number of Shares placed in the Offering. The Placement Agent Warrants have a term of five (5) years from the
commencement of sales under the Offering, are exercisable commencing six (6) months from the closing date, and have an exercise price
of $0.90 per share of Common Stock (equal to 100% of the combined public offering price per Common Unit).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company received
gross proceeds from the Offering of $4.5 million, before deducting Placement Agent fees and other offering expenses payable by the Company.
The net proceeds to the Company from the Offering, after deducting the Placement Agent&#8217;s fees and expenses and estimated offering
expenses (excluding proceeds to the Company, if any, from the future exercise of the Common Warrants and Placement Agent Warrants), were
approximately $3.9 million. The Company intends to use the net proceeds from the Offering as working capital for general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In conjunction with the
closing of the Offering, the Company entered into a Warrant Agency Agreement with Computershare Inc. (&#8220;Computershare Inc.&#8221;)
and its affiliate, Computershare Trust Company, N.A. (&#8220;Computershare Trust&#8221;) (collectively Computershare, Inc. and Computershare
Trust, &#8220;Computershare&#8221;) pursuant to which Computershare agreed to act as warrant agent with respect to the Warrants issued
by the Company in the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, the Company
(i) has agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares of the Company&#8217;s
(or its subsidiary&#8217;s) securities for a period of ninety (90) days from the closing of the Offering, subject to certain exceptions
and (ii) shall not effect or enter into an agreement to effect, any issuance by the Company or any of its subsidiaries of common stock
or common stock equivalents (or a combination of units thereof) involving a variable rate transaction for a period of one (1) year from
the closing of the Offering. Additionally, in connection with the Offering, each of the officers and directors of the Company entered
into lock-up agreements, pursuant to which they agreed not to sell or transfer any of the Company securities they hold, subject to certain
exceptions, during the sixty (60) day period following the closing of the Offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Purchase Agreement contains
customary conditions to closing, representations and warranties of the Company, and termination rights of the parties, as well as certain
indemnification obligations of the Company and ongoing covenants for the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The foregoing summaries of
the terms of the Common Warrants, the Pre-Funded Warrants, the Placement Agent Warrants, the Warrant Agency Agreement, the Purchase Agreement
and the Placement Agency Agreement do not purport to be complete and are subject to, and qualified in their entirety by, the forms of
such documents attached to this Current Report on Form 8-K (this &#8220;Current Report&#8221;) as Exhibits 4.1, 4.2, 4.3, 4.4, 10.1, and
10.2, respectively, and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #212529">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 4, 2025,
the Company issued a press release regarding the pricing of the Offering. A copy of the press release is furnished as Exhibit 99.1 hereto
and incorporated by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>Item 9.01 Financial Statements
and Exhibits. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b>(d) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1pt solid; vertical-align: top; width: 9%"><span style="font-size: 10pt"><b>Exhibit Number</b></span></td>
    <td style="padding-bottom: 1pt; vertical-align: top; width: 1%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="aethlon_ex0401.htm">Form of Common Warrant, dated September 4, 2025</a>.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="aethlon_ex0402.htm">Form of Pre-Funded Warrant, dated September 4, 2025</a>.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="aethlon_ex0403.htm">Placement Agent Warrant, dated September 4, 2025</a>.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/882291/000168316825006537/aethlon_ex0413.htm">Form of Warrant Agency Agreement by and between Aethlon Medical, Inc. and Computershare Inc. and its affiliate, Computershare Trust Company, N.A.</a> (incorporated by reference to Form S-1/A filed on
    August 29, 2025 as Exhibit 4.13)</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="aethlon_ex1001.htm">Form of Securities Purchase Agreement, dated September 4, 2025, by and between Aethlon Medical, Inc. and investors party thereto</a>.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="aethlon_ex1002.htm">Placement Agency Agreement, dated September 4, 2025 by and between Aethlon Medical, Inc. and Maxim Group, LLC</a>.</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">99.1</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><a href="aethlon_ex9901.htm">Press Release, dated September 4, 2025</a>.</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">104</span></td>
    <td style="vertical-align: top"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the inline XBRL Document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Date: September 9, 2025</span></td>
    <td colspan="2"><span style="font-size: 10pt"><b>Aethlon Medical, Inc.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td>
    <td><span style="font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 52%"><span style="font-size: 10pt">&#160;</span></td>
    <td style="width: 5%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; width: 43%"><span style="font-size: 10pt">/s/ James B. Frakes</span></td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">&#160;</span></td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Name:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td>
    <td style="vertical-align: bottom">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">James B. Frakes</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Chief Executive Officer and Chief Financial Officer</i></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-bottom: Black 1pt solid; border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>





<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKgkAQRb/Afxj2OUyX6sHHpCKyEInodckxlnRHZrfST+ovW5VouDAM9565QszEjra6RobrusjgjE1bK4dQYIWM5oY+ke4PCfhd4F1bx8q48fyBKXkGPbMMpVTeGKMvbbFMIFrM5SCIVkkcQ34UweCnZCpdonFa1aBMCTlTyxqd4n76cFYdGWr6seqCbDWZBOIwmuwPyCiWcKKXehM/LGRZKoLZOIHYMT1bn9p0Ds1AwqbGxtfZif4r+AIFFUqK -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>aethlon_ex0401.htm
<DESCRIPTION>FORM OF COMMON WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AETHLON
MEDICAL, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">Warrant Shares: _______</TD>
  <TD STYLE="text-align: right; width: 50%">Initial Exercise Date: September 4, 2025</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CUSIP: _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
September 4, 2025 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on September 4, 2030
(the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Aethlon Medical, Inc., a Nevada corporation
(the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository
Trust Company or its nominee (&ldquo;<U>DTC</U>&rdquo;) shall initially be the sole registered holder of this Warrant, subject to a Holder&rsquo;s
right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency Agreement, in which case this sentence
shall not apply. &ldquo;<U>Warrant Agency Agreement</U>&rdquo; means that certain warrant agency agreement, dated on or about the Initial
Exercise Date, between the Company and the Warrant Agent. &ldquo;<U>Warrant Agent</U>&rdquo; means the Transfer Agent and any successor
warrant agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated September 4, 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Notwithstanding the
foregoing in this Section 2(a), a holder whose interest in this Warrant is a beneficial interest in certificate(s) representing this Warrant
held in book-entry form through DTC (or another established clearing corporation performing similar functions), shall effect exercises
made pursuant to this Section 2(a) by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction
form for exercise, complying with the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable),
subject to a Holder&rsquo;s right to elect to receive a Definitive Warrant pursuant to the terms of the Warrant Agency Agreement, in which
case this sentence shall not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be <B>$</B>0.90, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(A) =&nbsp;&nbsp;&nbsp;&nbsp;as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable
Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B) =&nbsp;&nbsp;&nbsp;&nbsp;the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(X) =&nbsp;&nbsp;&nbsp;&nbsp;the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery
of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the
delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of
the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment
of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the
Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery
Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject
to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing
to $20 per Trading Day on the fifth (5th) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent
that is a participant in the Fast Automated Securities Transfer Program (FAST program) so long as this Warrant remains outstanding and
exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of
the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by notifying the Warrant
Agent or the Company of such rescission at any time prior to the delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e)</TD><TD STYLE="text-align: justify"><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not affect any exercise of this Warrant,
and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that
after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section
2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any reports or schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this
Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial
Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a
determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and
the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of
Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent
periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;
Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 4.99% (or 9.99% at the election of the Holder) of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice
to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such
notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time while this Warrant
is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other
property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to
such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pro Rata Distributions</U>. Except in the case of a Fundamental Transaction to which Section 3(e) below is applicable or to
which a notice under Section 3(g)(ii) below applies, during such time as this Warrant is outstanding, if the Company shall declare or
make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the
time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has
exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any
Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the outstanding common stock of the Company, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or
50% or more of the voting power of the outstanding common stock of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section
3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this
Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of
capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the
value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the
other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and the Successor Entity
may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other
Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that the Company, in consultation with its legal counsel, determines that any notice provided
in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company
shall comply with (i) its disclosure obligations under Regulation FD and (ii) the applicable instructions to Form 8-K. The Holder shall
remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time
during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by
the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company or Warrant Agent unless the Holder has assigned this Warrant in full, in which case,
the Holder shall surrender this Warrant to the Company or Warrant Agent within three (3) Trading Days of the date on which the Holder
delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may
be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Register</U>. The Warrant Agent (or, in the event a Holder elects to receive a Definitive Certificate (as defined in
the Warrant Agency Agreement), the Company) shall register this Warrant, upon records to be maintained by the Warrant Agent (or, in the
event a Holder elects to receive a Definitive Certificate, the Company) for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers,
shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City
of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of
New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other
provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in
any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, or e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 11555 Sorrento Valley Road, Suite 203, San Diego, CA 92121, Attention: James Frakes, email
address: accountspayable@aethlonmedical.com, or such other facsimile number, email address or address as the Company may specify for such
purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall
be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier service addressed
to each Holder at the facsimile number, e-mail address or address of such Holder appearing on the books of the Company. Any notice or
other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section on a day that is not
a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required
to be given. To the extent that the Company, in consultation with its legal counsel, determines that any notice provided in this Warrant
constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall comply
with (i) its disclosure obligations under Regulation FD and (ii) the applicable instructions to Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Agency Agreement.</U> If this Warrant is held in global form through DTC (or any successor depositary), this Warrant
is issued subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of
the Warrant Agency Agreement, the provisions of this Warrant shall govern and be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>AETHLON MEDICAL, Inc.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: #000000 1px solid; vertical-align: top">Name: James Frakes<BR> Title: Chief Executive Officer and Chief Financial
    Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#9;AETHLON
MEDICAL, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: _______________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _______________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><U>______________________________________</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD>______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD>______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Signature:<U> _____________________</U></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Address: ______________________</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Warrant Certificate Request Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT CERTIFICATE REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: Computershare Investor Services, as Warrant
Agent for Aethlon Medical, Inc. (the &ldquo;<U>Company</U>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of Common Stock Purchase
Warrants (&ldquo;<U>Warrants</U>&rdquo;) in the form of Global Warrants issued by the Company hereby elects to receive a Warrant Certificate
evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25px; text-align: justify; font-size: 10pt">1.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder of Warrants in form of Global Warrants: _____________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">2.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder in Warrant Certificate (if different from name of Holder of Warrants in form of Global Warrants): ________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">3.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Global Warrants: ___________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">4.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants for which Warrant Certificate shall be issued: __________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">5.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Global Warrants after issuance of Warrant Certificate, if any: ___________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">6.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Warrant Certificate shall be delivered to the following address:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate, the Holder is deemed to have surrendered the
number of Warrants in the form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: ______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Global Warrant Request Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GLOBAL WARRANT REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: Computershare Investor Services, as Warrant
Agent for Aethlon Medical, Inc. (the &ldquo;<U>Company</U>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of Common Stock Purchase
Warrants (&ldquo;<U>Warrants</U>&rdquo;) in the form of Warrant Certificates issued by the Company hereby elects to receive a Global Warrant
evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25px; text-align: justify; font-size: 10pt">1.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder of Warrants in form of Warrant Certificates: _____________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">2.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder in Global Warrant (if different from name of Holder of Warrants in form of Warrant Certificates): ________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">3.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Warrant Certificates: ___________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">4.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants for which Global Warrant shall be issued: __________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">5.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Warrant Certificates after issuance of Global Warrant, if any: ___________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">6.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Global Warrant shall be delivered to the following address:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Global Warrant Exchange and the issuance of the Global Warrant, the Holder is deemed to have surrendered
the number of Warrants in form of Warrant Certificates in the name of the Holder equal to the number of Warrants evidenced by the Global
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: ______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>aethlon_ex0402.htm
<DESCRIPTION>FORM OF PRE-FUNDED WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 4.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Aethlon
medical, inc. </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 54%; font-size: 10pt">Warrant Shares: [&nbsp;<FONT STYLE="font-family: Wingdings 2">&tilde;</FONT>&nbsp;]</TD>
    <TD STYLE="width: 46%; font-size: 10pt; text-align: right">Issue Date and Initial Exercise Date: September 4, 2025</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">THIS PRE-FUNDED COMMON STOCK PURCHASE
WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and until this Warrant is exercised in full (the &ldquo;<U>Termination
Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from <FONT STYLE="text-transform: uppercase">aethlon medical, inc.,
</FONT>a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to [ ] shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant
Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise
Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry
form and the Depository Trust Company or its nominee (&ldquo;<U>DTC</U>&rdquo;) shall initially be the sole registered holder of this
Warrant, subject to a Holder&rsquo;s right to elect to receive a Warrant in certificated form pursuant to the terms of the Warrant Agency
Agreement, in which case this sentence shall not apply. &ldquo;<U>Warrant Agency Agreement</U>&rdquo; means that certain warrant agency
agreement, dated on or about the Initial Exercise Date, between the Company and the Warrant Agent. &ldquo;<U>Warrant Agent</U>&rdquo;
means the Transfer Agent and any successor warrant agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated September 4, 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">a)</TD><TD STYLE="text-align: justify"><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in
whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the
Company of (i) a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto
(the &ldquo;<U>Notice of Exercise</U>&rdquo;) and (ii) the aggregate Exercise Price for the Warrant Shares specified in the applicable
Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank (unless the cashless exercise procedure specified
in Section 2(c) below is specified in the applicable Notice of Exercise). No ink-original Notice of Exercise shall be required, nor shall
any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein
to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all
of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant
to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company.
Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall
have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number
of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the
date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such
notice. Notwithstanding the foregoing, with respect to any Notice(s) of Exercise delivered on or prior to 4:00 p.m. (New York City time)
on the Trading Date prior to the Initial Exercise Date, which may be delivered at any time after the time of execution of the Purchase
Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time) on the Initial
Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date for purposes hereunder, provided that payment of
the aggregate Exercise Price (other than in the case of a cashless exercise) is received by such Warrant Share Delivery Date. <B>The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given
time may be less than the amount stated on the face hereof. </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">Notwithstanding the foregoing in this Section 2(a), a holder
whose interest in this Warrant is a beneficial interest in certificate(s) representing this Warrant held in book-entry form through DTC
(or another established clearing corporation performing similar functions), shall effect exercises made pursuant to this Section 2(a)
by delivering to DTC (or such other clearing corporation, as applicable) the appropriate instruction form for exercise, complying with
the procedures to effect exercise that are required by DTC (or such other clearing corporation, as applicable), subject to a Holder&rsquo;s
right to elect to receive a Definitive Warrant pursuant to the terms of the Warrant Agency Agreement, in which case this sentence shall
not apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise Price</U>.
The aggregate exercise price of this Warrant, except for a nominal exercise price of $0.001 per Warrant Share, was pre-funded to the Company
on or prior to the Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.001
per Warrant Share) shall be required to be paid by the Holder to any Person to effect any exercise of this Warrant. The Holder shall not
be entitled to the return or refund of all, or any portion, of such pre-paid aggregate exercise price under any circumstance or for any
reason whatsoever, including in the event this Warrant shall not have been exercised prior to the Termination Date. The remaining unpaid
exercise price per share of Common Stock under this Warrant shall be $0.001, subject to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Cashless Exercise</U>.
This Warrant may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder
shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(A)</TD><TD STYLE="text-align: justify">=&#9;as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice
of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading
Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, or (ii)
the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise
is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading
Day;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(B)</TD><TD STYLE="text-align: justify">=&#9;the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(X)</TD><TD STYLE="text-align: justify">=&#9;the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with
the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant. The Company
agrees not to take any position contrary to this Section 2(c), except to the extent required by applicable law, rules or regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if the Common Stock is not then listed or quoted for trading on a Trading
Market and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to
its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (c) in all other cases, the
fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Company and reasonably
acceptable to the Purchasers of a majority in interest of the Securities then outstanding, the fees and expenses of which shall be paid
by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding anything
herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this
Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">d) <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">i. <U>Delivery of Warrant
Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the
Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company through
its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system and either
(A) the Holder has sold the Warrant Shares pursuant to an effective registration statement registering the resale of the Warrant Shares
by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations or any requirement
for the Company to comply with the current public information obligations of Rule 144(c) pursuant to Rule 144 (assuming cashless exercise
of the Warrants), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of
the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address
specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the
Company of the Notice of Exercise (and receipt of the aggregate Exercise Price) and (ii) the number of Trading Days comprising the Standard
Settlement Period after the delivery to the Company of the Notice of Exercise (and receipt of the aggregate Exercise Price) (such date,
the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise and receipt of payment of the aggregate
Exercise Price (other than in the case of a cashless exercise), the Holder shall be deemed for all corporate purposes to have become the
holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of
the Warrant Shares. The Company agrees to maintain a transfer agent that is a participant in the Fast Automated Securities Transfer Program
(FAST program) so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise. Notwithstanding the foregoing, with respect to any
Notice(s) of Exercise delivered on or prior to 12:00 p.m. (New York City time) on the Initial Exercise Date, which may be delivered at
any time after the time of execution of the Purchase Agreement, the Company agrees to deliver the Warrant Shares subject to such notice(s)
by 4:00 p.m. (New York City time) on the Initial Exercise Date and the Initial Exercise Date shall be the Warrant Share Delivery Date
for purposes hereunder, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received
by such Warrant Share Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 31.5pt">ii. <U>Delivery of
New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon
surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the
rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117.35pt; text-align: justify; text-indent: 31.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">iii. <U>Rescission Rights</U>.
If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant
Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">iv. <U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As
to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">v. <U>Charges, Taxes
and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">vi. <U>Closing of
Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 117pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for exercises of this Warrant
that are not in compliance with the Beneficial Ownership Limitation, provided this limitation of liability shall not apply if the Holder
has detrimentally relied on outstanding share information provided by the Company or the Transfer Agent. In addition, a determination
as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and
regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock,
a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or
annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent
written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written request
of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock
then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date
as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall
be 4.99% (or 9.99% at the election of the Holder) of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may increase
or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in
no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any
increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such notice is delivered to
the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with
the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended
Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>. <U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Stock Dividends
and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution
or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which,
for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides
outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding
shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of
capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator
shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise
of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment
made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled
to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision,
combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>[Reserved]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Subsequent Rights
Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common
Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares
of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to
such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without
limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale
of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s right
to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result
of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Pro Rata Distributions</U>.
Except in the case of a Fundamental Transaction to which Section 3(e) below is applicable or to which a notice under Section 3(g)(ii)
below applies, during such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the
record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>,
that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of more than 50% of the outstanding Common Stock or more than 50% of the voting
power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification,
reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively
converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group
acquires more than 50% of the outstanding shares of Common Stock or more than 50% of the voting power of the common equity of the Company
(each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction, at the option of the Holder (without regard to the Beneficial Ownership Limitation in Section 2(e) on the exercise of this
Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation,
and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction
(without regard to any limitation in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration
issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.
If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then
the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such
Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor
(the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant and the other
Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at
the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value
of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares
of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the
consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence
of any such Fundamental Transaction, the Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Warrant (so that
from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other
Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor
Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise
every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations
of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor
Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall
be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient authorized shares
of Common Stock for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Adjustment to
Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver
to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant
Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Notice to Allow
Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock,
(B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall authorize
the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class
or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the
Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or
substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or
property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the
Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email address as it shall appear
upon the Warrant Register of the Company, at least three calendar days prior to the applicable record or effective date hereinafter specified,
a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,
or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions,
redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer
or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of
record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in
the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 4. Transfer of
Warrant.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws, this Warrant and all rights hereunder (including, without limitation, any registration
rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated
agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its
agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if
required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company on the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New Warrants</U>.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the issue date and shall be identical with this Warrant except
as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant Register</U>.
The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the
absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual
notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No Rights as Stockholder
Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i). Without limiting any rights of a Holder to
receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c), in no event shall the Company be required to net
cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss, Theft, Destruction
or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft
or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting
of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver
a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Saturdays, Sundays,
Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein
shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">i. The Company covenants
that, following the Initial Exercise Date and during the period the Warrant is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights
under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who
are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company
will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation
of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company
covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon
exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized,
validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">ii. Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify; text-indent: 0.5in">iii. Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver and
Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver
of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this Warrant
or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in
any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>. Any
notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance
with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation of
Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors and
Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit
of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions
of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder
or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">o) <U>Warrant Agency
Agreement</U>. If this Warrant is held in global form through DTC (or any successor depositary), this Warrant is issued subject to the
Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of the Warrant Agency Agreement,
the provisions of this Warrant shall govern and be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>AETHLON MEDICAL</B></FONT><B>,
    INC.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; width: 5%; font-size: 10pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%; font-size: 10pt">&#8239;&#8239;&#8239;&#8239;&#8239;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Name:</TD>
    <TD STYLE="font-size: 10pt">James Frakes</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To: AETHLON
MEDICAL</FONT>, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(1) The undersigned hereby elects
to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(2) Payment shall take the form
of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
in lawful money of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">(3) Please issue said Warrant Shares
in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Date: _______________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B></B></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing Warrant,
execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing Warrant and all
rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; font-size: 10pt; text-align: justify">Name:</TD>
    <TD STYLE="width: 48%; font-size: 10pt; text-align: justify">______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Address:</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><U>______________________________________</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Phone Number:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Email Address:</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">______________________________________</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Dated: _______________ __, ______</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Holder&rsquo;s Signature:_________________________</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: justify">Holder&rsquo;s Address: _________________________</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>4
<FILENAME>aethlon_ex0403.htm
<DESCRIPTION>PLACEMENT AGENT WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 4.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>COMMON STOCK PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>AETHLON
MEDICAL, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">Warrant Shares: 200,000</TD>
  <TD STYLE="text-align: right; width: 50%">Initial Exercise Date: September 4, 2025</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">CUSIP: _______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: left; text-indent: 1.5in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS COMMON STOCK PURCHASE WARRANT
(the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, Maxim Group, LLC or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time and from
time to time from and after the 181<SUP>st</SUP> day (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) immediately following the date of
effectiveness of that certain registration statement on Form S-1 (File No. 333-289745) filed by the Company, in accordance with FINRA
Rule 5110(g)(1), and through and including the five year anniversary of the date of effectiveness of that certain registration statement
on Form S-1 (File No. 333-289745), which such date is September 4, 2030 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter,
to subscribe for and purchase from Aethlon Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to 200,000 shares
(as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common
Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&#9;<U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Purchase Agreement</U>&rdquo;), dated September 4, 2025, among the Company and the purchasers signatory thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&#9;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any
time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed
PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree
that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exercise Price</U>. The exercise price per share of Common Stock under this Warrant shall be $______, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole
or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(A) =&nbsp;&nbsp;&nbsp;&nbsp;as applicable:
(i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1)
both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant
to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b) of Regulation
NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading
Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading
Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution of the applicable
Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered
within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day)
pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise
is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular
trading hours&rdquo; on such Trading Day;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">(B) =&nbsp;&nbsp;&nbsp;&nbsp;the Exercise
Price of this Warrant, as adjusted hereunder; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">(X) =&nbsp;&nbsp;&nbsp;&nbsp;the number
of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were
by means of a cash exercise rather than a cashless exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">If
Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the
Securities Act, the Warrant Shares shall take on the registered characteristics of the Warrants being exercised.&nbsp;&nbsp;The Company
agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&nbsp;in
all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by
the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp; if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser
selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company,
the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant
to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">d)</TD><TD STYLE="text-align: justify"><U>Mechanics of Exercise</U>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted
by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository
Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in
such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of
the Warrant Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate,
registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which
the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is
the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery
of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the
delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of
the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment
of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the
Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery
Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject
to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing
to $20 per Trading Day on the fifth (5th) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share
Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent
that is a participant in the Fast Automated Securities Transfer Program (FAST program) so long as this Warrant remains outstanding and
exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of
the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request
of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new
Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall
in all other respects be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant
to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by notifying the Warrant
Agent or the Company of such rescission at any time prior to the delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions
of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares
of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer
tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the
Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;
<U>provided</U>, <U>however</U>, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder,
this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and
the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.
The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository
Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of
the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">e)</TD><TD STYLE="text-align: justify"><U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not affect any exercise of this Warrant,
and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that
after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s
Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution
Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of
the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties
shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is
being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised
portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion
of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock
Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the
Holder or any of its Affiliates or Attribution Parties.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section
2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any reports or schedules required to be filed in accordance
therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable
(in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this
Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be
the Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial
Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination. In addition, a
determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and
the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of
Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent
periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a
more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;
Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates
or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial
Ownership Limitation</U>&rdquo; shall be 4.99% (or 9.99% at the election of the Holder) of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice
to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial
Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect
to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61<SUP>st</SUP> day after such
notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in
strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent
with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&#9;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or
otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable
in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise
of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way
of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares
of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction
of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before
such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the
number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this
Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record
date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after
the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Reserved</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time while this Warrant
is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other
property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder
will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard
to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder
exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent
(or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to
such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding
the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Pro Rata Distributions</U>. Except in the case of a Fundamental Transaction to which Section 3(e) below is applicable or to
which a notice under Section 3(g)(ii) below applies, during such time as this Warrant is outstanding, if the Company shall declare or
make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of
return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options
by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding
the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the
beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution
shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation). To the extent that this Warrant has not been partially or completely exercised at the
time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of the Holder until the Holder has
exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in
one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any
Subsidiary, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or
substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer
or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Common Stock or 50% or more of the voting power of the outstanding common stock of the Company, (iv) the Company, directly or indirectly,
in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory
share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other
business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with
another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding shares of Common Stock or
50% or more of the voting power of the outstanding common stock of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section
3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this
Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of
capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the
value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting
the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory
in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for the Company (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the
other Transaction Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and the Successor Entity
may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant and the other
Transaction Documents with the same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given
date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form)
on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be
entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification,
consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other
property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to
deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to
be specified in such notice. To the extent that the Company, in consultation with its legal counsel, determines that any notice provided
in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company
shall comply with (i) its disclosure obligations under Regulation FD and (ii) the applicable instructions to Form 8-K. The Holder shall
remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering
such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Voluntary Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time
during the term of this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by
the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&#9;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transferability</U>. This Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written
assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient
to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall
execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company or Warrant Agent unless the Holder has assigned this Warrant in full, in which case,
the Holder shall surrender this Warrant to the Company or Warrant Agent within three (3) Trading Days of the date on which the Holder
delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may
be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued. This Warrant may not be sold, transferred,
assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result
in the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of effectiveness
of that certain registration statement on Form S-1 (File No. 333-289745) filed by the Company, except as provided in FINRA Rule 5110(g)(2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>New Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office
of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division
or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided
or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of
this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Register</U>. The Warrant Agent (or, in the event a Holder elects to receive a Definitive Certificate (as defined in
the Warrant Agency Agreement), the Company) shall register this Warrant, upon records to be maintained by the Warrant Agent (or, in the
event a Holder elects to receive a Definitive Certificate, the Company) for that purpose (the &ldquo;<U>Warrant Register</U>&rdquo;),
in the name of the record Holder hereof from time to time. The Company and the Warrant Agent may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&#9;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights,
dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly
set forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant
to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be
required to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right
required or granted herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding
Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authorized Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers,
shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City
of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of
New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that
it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient
venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any
other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant,
the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees
and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions</U>. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered,
and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder
shall operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other
provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in
any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses
including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting
any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, or e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at 11555 Sorrento Valley Road, Suite 203, San Diego, CA 92121, Attention: James Frakes, email
address: accountspayable@aethlonmedical.com, or such other facsimile number, email address or address as the Company may specify for such
purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall
be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier service addressed
to each Holder at the facsimile number, e-mail address or address of such Holder appearing on the books of the Company. Any notice or
other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the time of transmission, if such
notice or communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section
prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number or via e-mail at the e-mail address set forth in this Section on a day that is not
a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing,
if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required
to be given. To the extent that the Company, in consultation with its legal counsel, determines that any notice provided in this Warrant
constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall comply
with (i) its disclosure obligations under Regulation FD and (ii) the applicable instructions to Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant
to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the
Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company
or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages,
will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate
compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to
assert the defense in any action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby
shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted
assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and
shall be enforceable by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment</U>. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company
and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and
valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision
shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Headings</U>. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be
deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Warrant Agency Agreement.</U> If this Warrant is held in global form through DTC (or any successor depositary), this Warrant
is issued subject to the Warrant Agency Agreement. To the extent any provision of this Warrant conflicts with the express provisions of
the Warrant Agency Agreement, the provisions of this Warrant shall govern and be controlling.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I><BR STYLE="clear: both">
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><B>AETHLON MEDICAL, Inc.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-top: #000000 1px solid; vertical-align: top">Name: James B. Frakes<BR> Title: Chief Executive Officer and Chief
    Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">To:&#9;AETHLON
MEDICAL, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant
(only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes,
if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Payment shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; in lawful money
of the United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&#9744; if permitted the
cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise
this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in
subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;
</FONT>Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: _______________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _______________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD>
    <TD STYLE="width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Address:</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><U>______________________________________</U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Phone Number:</TD>
    <TD>______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Email Address:</TD>
    <TD>______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Signature:<U> _____________________</U></TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">Holder&rsquo;s Address: ______________________</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Warrant Certificate Request Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WARRANT CERTIFICATE REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: Computershare Investor Services, as Warrant
Agent for Aethlon Medical, Inc. (the &ldquo;<U>Company</U>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of Common Stock Purchase
Warrants (&ldquo;<U>Warrants</U>&rdquo;) in the form of Global Warrants issued by the Company hereby elects to receive a Warrant Certificate
evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25px; text-align: justify; font-size: 10pt">1.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder of Warrants in form of Global Warrants: _____________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">2.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder in Warrant Certificate (if different from name of Holder of Warrants in form of Global Warrants): ________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">3.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Global Warrants: ___________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">4.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants for which Warrant Certificate shall be issued: __________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">5.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Global Warrants after issuance of Warrant Certificate, if any: ___________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">6.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Warrant Certificate shall be delivered to the following address:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Warrant Exchange and the issuance of the Warrant Certificate, the Holder is deemed to have surrendered the
number of Warrants in the form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the Warrant Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: ______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Global Warrant Request Notice</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">GLOBAL WARRANT REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To: Computershare Investor Services, as Warrant
Agent for Aethlon Medical, Inc. (the &ldquo;<U>Company</U>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned Holder of Common Stock Purchase
Warrants (&ldquo;<U>Warrants</U>&rdquo;) in the form of Warrant Certificates issued by the Company hereby elects to receive a Global Warrant
evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 25px; text-align: justify; font-size: 10pt">1.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder of Warrants in form of Warrant Certificates: _____________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">2.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Name of Holder in Global Warrant (if different from name of Holder of Warrants in form of Warrant Certificates): ________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">3.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Warrant Certificates: ___________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">4.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants for which Global Warrant shall be issued: __________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">5.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Number of Warrants in name of Holder in form of Warrant Certificates after issuance of Global Warrant, if any: ___________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">6.</TD>
    <TD STYLE="text-align: justify; font-size: 10pt">Global Warrant shall be delivered to the following address:</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby acknowledges and agrees
that, in connection with this Global Warrant Exchange and the issuance of the Global Warrant, the Holder is deemed to have surrendered
the number of Warrants in form of Warrant Certificates in the name of the Holder equal to the number of Warrants evidenced by the Global
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ____________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: ______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>aethlon_ex1001.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center; text-indent: -0.5in"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This Securities Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) is dated as of September 4, 2025 between Aethlon Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively the &ldquo;<U>Purchasers</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">WHEREAS, subject to the terms
and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act (as defined below)
as to the Shares, the Pre-Funded Warrants and the Common Warrants, the Company desires to issue and sell to each Purchaser, and each Purchaser,
severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, IN CONSIDERATION
of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are
hereby acknowledged, the Company and each Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE I.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.1 <U>Definitions</U>. In addition
to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth
in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Acquiring
Person</U>&rdquo; shall have the meaning ascribed to such term in Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Action</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(j).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Board of Directors</U>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by
law to remain closed; <U>provided</U>, <U>however</U>, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are
open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Warrants</U>&rdquo;
means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof,
which warrants shall be exercisable immediately and have a term of exercise equal to five (5) years, in the form of <U>Exhibit A</U> attached
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Warrant
Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Securities pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchasers&rsquo; obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the first (1st) Trading
Day following the date hereof (or the second (2nd) Trading Day following the date hereof if this Agreement is executed after 4:00 PM EST
but prior to 11:59 PM EST).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock</U>&rdquo;
means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter
be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common Stock
Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any
time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any
time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date
hereof, unless otherwise instructed as to an earlier time by the Placement Agent, and (ii) if this Agreement is signed between midnight
(New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:01 a.m. (New York City time) on the date hereof,
unless otherwise instructed as to an earlier time by the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Evaluation
Date</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exempt Issuance</U>&rdquo;
means the issuance of (a) shares of Common Stock or options to employees, officers, consultants or directors of the Company pursuant to
any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities
upon the exercise or exchange of or conversion of any Securities issued hereunder, and/or other securities exercisable or exchangeable
for or convertible into shares of Common Stock issued and outstanding on the date of this Agreement, provided that such securities have
not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange
price or conversion price of such securities (other than in connection with stock splits or combinations), and (c) securities issued pursuant
to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that any such
issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company
or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company additional benefits
in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the
purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FCPA</U>&rdquo;
means the Foreign Corrupt Practices Act of 1977, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>FDCA</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>GAAP</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(aa).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; shall have the meaning ascribed to such term in Section 3.1(p).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lock-Up Agreement</U>&rdquo;
means the Lock-Up Agreement, dated as of the date hereof, by and among the Company and the directors and officers of the Company, in the
form of <U>Exhibit B</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Adverse
Effect</U>&rdquo; shall have the meaning assigned to such term in Section 3.1(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material Permits</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(n).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per Share
Purchase Price</U>&rdquo; equals $0.90, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of the Common Stock that occur after the date of this Agreement; provided that the purchase price per Pre-Funded
Warrant shall be the Per Share Purchase Price minus $0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Placement
Agent</U>&rdquo; means Maxim Group LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant</U>&rdquo; means, collectively, the Pre-Funded Common Stock purchase warrants delivered to the Purchasers at the Closing in accordance
with Section 2.2(a) hereof, which Pre-Funded Warrants shall be exercisable immediately upon issuance and shall expire in accordance with
the terms thereof, in the form of <U>Exhibit C</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Pre-Funded
Warrant Shares</U>&rdquo; means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition), whether commenced or threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Product</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(hh).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus</U>&rdquo;
means the final prospectus filed for the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Prospectus
Supplement</U>&rdquo; means the supplement to the Prospectus complying with Rule 424(b) of the Securities Act that is filed with the Commission
and delivered by the Company to each Purchaser at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Purchaser
Party</U>&rdquo; shall have the meaning ascribed to such term in Section 4.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the effective registration statement with Commission File No. 333-289745 which registers the sale of the Shares
and Pre-Funded Warrants, Common Warrants, Pre-Funded Warrant Shares and Common Warrant Shares to the Purchasers., and the common shares
underlying the warrants held by the named selling securityholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Required Approvals</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(e).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 144</U>&rdquo;
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Rule 424</U>&rdquo;
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(h).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities</U>&rdquo;
means the Shares, the Pre-Funded Warrants, the Pre-Funded Warrant Shares, the Common Warrants and the Common Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the shares of Common Stock issued or issuable to each Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short Sales</U>&rdquo;
means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include
locating and/or borrowing shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, as to each Purchaser, the aggregate amount to be paid for Shares and Common Warrants purchased hereunder as specified
below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo; in
United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company as set forth on <U>in the SEC Reports</U>, and shall, where applicable, also include any direct or
indirect subsidiary of the Company formed or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the
NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the
OTCID Basic Market, OTCQB or the OTCQX (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Pre-Funded Warrants, the Common Warrants, all exhibits and schedules thereto and hereto
and any other documents or agreements executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer Agent</U>&rdquo;
means Computershare Investor Services, the current transfer agent of the Company, with an address at P.O. Box 30170, College Station,
TX 77842, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE II.<BR>
</B>PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.1 <U>Closing</U>. On the Closing
Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery of this
Agreement by the parties hereto, the Company agrees to sell, and each Purchaser, severally and not jointly, agrees to purchase, (i) such
number of Shares or (ii) a Pre-Funded Warrant to purchase such number of shares of Common Stock, and (iii) a Common Warrant to purchase
such number of shares of Common Stock, in each case, as set forth on such Purchaser&rsquo;s signature page hereto, for an aggregate total
purchase price equal to the Subscription Amount set forth on such Purchaser&rsquo;s signature page hereto. Each Purchaser&rsquo;s Subscription
Amount as set forth on the signature page hereto executed by such Purchaser shall be made available for &ldquo;Delivery Versus Payment&rdquo;
settlement with the Company or its designee. The Company shall deliver to each Purchaser its respective Shares, Pre-Funded Warrant, and
Common Warrant as determined pursuant to Section 2.2(a), and the Company and each Purchaser shall deliver the other items set forth in
Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2 and 2.3, the Closing
shall take place remotely by electronic transfer of the Closing documentation. Unless otherwise directed by the Placement Agent, settlement
of the Shares shall occur via &ldquo;Delivery Versus Payment&rdquo; (&ldquo;<U>DVP</U>&rdquo;) (i.e., on the Closing Date, the Company
shall issue the Shares registered in the Purchasers&rsquo; names and addresses and released by the Transfer Agent directly to the account(s)
at the Placement Agent identified by each Purchaser; upon receipt of such Shares, the Placement Agent shall promptly electronically deliver
such Shares to the applicable Purchaser, and payment therefor shall be made by the Placement Agent (or its clearing firm) by wire transfer
to the Company). Notwithstanding the foregoing, with respect to any Notice(s) of Exercise (as defined in the Pre-Funded Warrants) delivered
on or prior to 12:00 p.m. (New York City time) on the Closing Date, which may be delivered at any time after the time of execution of
this Agreement, the Company agrees to deliver the Pre-Funded Warrant Shares subject to such notice(s) by 4:00 p.m. (New York City time)
on the Closing Date and the Closing Date shall be the Warrant Share Delivery Date (as defined in the Pre-Funded Warrants) for purposes
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2.2 <U>Deliveries</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) On or prior to the
Closing Date (except as indicated below), the Company shall deliver or cause to be delivered to each Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i) this Agreement duly
executed by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii) a legal opinion and
negative assurance letter of Procopio Cory Hargreaves &amp; Savitch, LLP a, each such legal opinion, substantially in form and substance
reasonably satisfactory to the Placement Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii) subject to the last
sentence of Section 2.1, the Company shall have provided each Purchaser with the Company&rsquo;s wire instructions, on Company letterhead;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iv) subject to the last
sentence of Section 2.1, a copy of the irrevocable instructions to the Transfer Agent instructing the Transfer Agent to deliver on an
expedited basis via The Depository Trust Company Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) a number of Shares
equal to the number of Shares set forth on such Purchaser&rsquo;s signature page hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(v) a Pre-Funded Warrant
registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to such Purchaser&rsquo;s Subscription
Amount divided by the Per Share Purchase Price (rounded down to the nearest whole Share) (such number the &ldquo;<U>Specified Base Share
Number</U>&rdquo;), <I>minus</I> the number of Shares required to be delivered pursuant to Section 2.2(a)(iv), with an exercise price
equal to $0.001, subject to adjustment therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(vi) a Common Warrant
registered in the name of such Purchaser to purchase up to a number of shares of Common Stock equal to 100% of the Specified Base Share
Number, with an exercise price equal to the Per Share Purchase Price, subject to adjustment therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(vii) a letter of Haskell
&amp; White LLP and Baker Tilly U.S. LLP on the date hereof and on the Closing Date, addressed to the Placement Agent, confirming that
they are independent registered public accountants within the meaning of the Securities Act and are in compliance with the applicable
requirements relating to the qualifications of accountants under Rule 2-01 of Regulation S-X of the Commission, and confirming, as of
the date of each such letter (or, with respect to matters involving changes or developments since the respective dates as of which specified
financial information is given in the Registration Statement, the Preliminary Prospectus and the Prospectus, as of a date not prior to
the date hereof or more than five days prior to the date of such letter), the conclusions and findings of said firms with respect to the
financial information and other matters required by the Placement Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(viii) the duly executed
Lock-Up Agreements;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ix) such information
and documents as the Placement Agent and counsel for the Placement Agent may reasonably require for the purposes of enabling them to pass
upon the issuance and sale of the Securities as contemplated herein, or in order to evidence the accuracy of any of the representations
and warranties, or the satisfaction of any of the conditions or agreements, herein contained;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(x) At the Closing Date,
there shall be furnished to the Placement Agent either: (a) a certificate, dated the date of its delivery, signed by each of the Chief
Executive Officer and the Chief Financial Officer of the Company, in their capacities as such, and not individually, in form and substance
reasonably satisfactory to the Placement Agent and counsel to the Placement Agent, certifying and confirming the satisfaction of certain
closing conditions referenced in Section 2.3(b), such certificate an &ldquo;<U>Officer&rsquo;s Certificate,</U>&rdquo; or, in the alternative,
(b) a written intellectual property opinion, dated the Closing Date and reasonably satisfactory in form and substance to the Placement
Agent and its counsel from the Company&rsquo;s intellectual property counsel;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(xi) the Prospectus and
Prospectus Supplement (which may be delivered in accordance with Rule 172 under the Securities Act); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(xii) the written intellectual
property opinion, dated the Closing Date reasonably satisfactory in form and substance to the Placement Agent and its counsel from Knobbe
Martens as intellectual property counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) On or prior to the
Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i) this Agreement duly
executed by such Purchaser; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii) such Purchaser&rsquo;s
Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company or its designee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.3 <U>Closing Conditions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) The obligations
of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i) the accuracy in all
material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) on the Closing Date
of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall
be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality, in all respects) as
of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii) all obligations,
covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii) the delivery by
each Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) The respective obligations
of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(i) the accuracy in all
material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects)
when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date
therein in which case they shall be accurate in all material respects or, to the extent representations or warranties are qualified by
materiality or Material Adverse Effect, in all respects) as of such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(ii) all obligations,
covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iii) the delivery by
the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(iv) there shall have
been no Material Adverse Effect with respect to the Company since the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(v) from the date hereof
to the Closing Date, no stop order suspending the effectiveness of any Registration Statement shall have been issued and no proceedings
for that purpose shall have been instituted or contemplated by the Commission, trading in the Common Stock shall not have been suspended
by the Commission or the Company&rsquo;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally
as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on securities
whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United
States or New York State authorities nor shall there have occurred any material outbreak or escalation of hostilities or other national
or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case,
in the reasonable judgment of such Purchaser, makes it impracticable or inadvisable to purchase the Securities at the Closing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">(vi) The Company has,
or has the ability to use, all of its Intellectual Property Rights and, as of the applicable Closing Date, there is no pending or threatened
interference, reissue, reexamination, derivation, post-grant review, <I>inter partes</I> review, or opposition proceeding involving any
of the Company&rsquo;s Intellectual Property Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE III.<BR>
</B>REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.1 <U>Representations and Warranties
of the Company</U>. Except as explicitly described in the SEC Reports, which descriptions shall be deemed a part hereof and shall qualify
any representation or otherwise made herein to the extent of the disclosure contained in the applicable SEC Report, the Company hereby
makes the following representations and warranties to each Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Subsidiaries</U>.
All of the direct and indirect subsidiaries of the Company are set forth in the SEC Reports. The Company owns, directly or indirectly,
all of the capital stock or other equity interests of each Subsidiary which it owns, free and clear of any Liens, and all of the issued
and outstanding shares of capital stock of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive
and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to the Subsidiaries
or any of them in the Transaction Documents shall be disregarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Organization
and Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite power and authority to
own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in
violation nor default of any of the provisions of its respective certificate or articles of incorporation, bylaws or other organizational
or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes such qualification
necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected
to result in: (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and the Subsidiaries,
taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material respect on a timely basis
its obligations under any Transaction Document (any of (i), (ii) or (iii), a &ldquo;<U>Material Adverse Effect</U>&rdquo;) and no Proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) <U>Authorization;
Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The
execution and delivery of this Agreement and each of the other Transaction Documents by the Company and the consummation by it of the
transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further
action is required by the Company, the Board of Directors, a committee of the Board of Directors or the Company&rsquo;s stockholders in
connection herewith or therewith, in each case, other than in connection with the Required Approvals. This Agreement and each other Transaction
Document to which it is a party has been (or upon delivery will have been) duly executed by the Company and, when delivered in accordance
with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms, except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization,
moratorium and other laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating
to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(d) <U>No Conflicts</U>.
The execution, delivery and performance by the Company of this Agreement and the other Transaction Documents to which it is a party, the
issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not
(i) conflict with or violate any provision of the Company&rsquo;s or any Subsidiary&rsquo;s certificate or articles of incorporation,
bylaws or other organizational or charter documents, or (ii) conflict with, or constitute a default (or an event that with notice or lapse
of time or both would become a default) under, result in the creation of any Lien upon any of the properties or assets of the Company
or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation
(with or without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or
Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any property or asset
of the Company or any Subsidiary is bound or affected, or (iii) subject to the Required Approvals, conflict with or result in a violation
of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which
the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset
of the Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii) and (iii), such as could not have or reasonably
be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(e) <U>Filings, Consents
and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any
filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with
the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to
Section 4.4 of this Agreement, (ii) the filing with the Commission of the Prospectus Supplement, and (iii) application(s) to each applicable
Trading Market for the listing of the Shares, the Pre-Funded Warrant Shares and the Common Warrant Shares for trading thereon in the time
and manner required thereby (collectively, the &ldquo;<U>Required Approvals</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(f) <U>Issuance of
the Securities; Registration</U>. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction
Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Pre-Funded
Warrant Shares, when issued in accordance with the terms of the Pre-Funded Warrants, will be validly issued, fully paid and nonassessable,
free and clear of all Liens imposed by the Company. The Common Warrant Shares, when issued in accordance with the terms of the Common
Warrants, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has prepared
and filed the Registration Statement in conformity with the requirements of the Securities Act, which became effective on 4, 2025, including
the Prospectus, and such amendments and supplements thereto as may have been required to the date of this Agreement. The Registration
Statement is effective under the Securities Act and no stop order preventing or suspending the effectiveness of the Registration Statement
or suspending or preventing the use of the Prospectus has been issued by the Commission and no proceedings for that purpose have been
instituted or, to the knowledge of the Company, are threatened by the Commission. At the time the Registration Statement and any amendments
thereto became effective, at the date of this Agreement and at the Closing Date, the Registration Statement and any amendments thereto
conformed and will conform in all material respects to the requirements of the Securities Act and did not and will not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein
not misleading; and the Prospectus and any amendments or supplements thereto, at the time the Prospectus or any amendment or supplement
thereto was issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the Securities
Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(g) <U>Capitalization</U>.
The capitalization of the Company as of March 31, 2025 is as set forth in the SEC Reports. The Company has not issued any capital stock
since its most recently filed periodic report under the Exchange Act, other than pursuant to (i) the exercise of employee stock options
and granting of restricted stock units under the Company&rsquo;s stock option plans and (ii) the issuance of shares of Common Stock to
employees pursuant to the Company&rsquo;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock
Equivalents outstanding as of the date of the most recently filed periodic report under the Exchange Act. No Person has any right of first
refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction
Documents. Except as a result of the purchase and sale of the Securities and as set forth in the SEC Reports, there are no outstanding
options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or
obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares
of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements by which the Company
or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any
Subsidiary. The issuance and sale of the Securities will not obligate the Company or any Subsidiary to issue shares of Common Stock or
other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary
with any provision that adjusts the exercise, conversion, exchange or reset price of such security or instrument upon an issuance of securities
by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any
redemption or similar provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any
Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock appreciation
rights or &ldquo;phantom stock&rdquo; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock
of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued in compliance with all federal and
state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe
for or purchase securities. Subject to any stockholder approval that may be requested by the Nasdaq Stock Market LLC, no further approval
or authorization of any stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are
no stockholders agreements, voting agreements or other similar agreements with respect to the Company&rsquo;s capital stock to which the
Company is a party or, to the knowledge of the Company, between or among any of the Company&rsquo;s stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(h) <U>SEC Reports;
Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by
the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the two years preceding
the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials,
including the exhibits thereto and documents incorporated by reference therein, together with the Prospectus and the Prospectus Supplement,
being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;) on a timely basis or has received a valid extension of
such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the
SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none
of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated
therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.
The Company has never been an issuer subject to Rule 144(i) under the Securities Act, or, if it has been an issuer subject to Rule 144(i),
it is not currently a &ldquo;shell company&rdquo; and at least one year has passed since it filed &ldquo;Form 10 Information&rdquo; with
the Commission. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting
requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements
have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the
periods involved (&ldquo;<U>GAAP</U>&rdquo;), except as may be otherwise specified in such financial statements or the notes thereto and
except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material respects
the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations
and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>Material Changes;
Undisclosed Events, Liabilities or Developments</U>. Since the date of the latest audited financial statements included within the SEC
Reports, except as set forth in the SEC Reports, (i) there has been no event, occurrence or development that has had or that could reasonably
be expected to result in a Material Adverse Effect, (ii) the Company has not incurred any liabilities (contingent or otherwise) other
than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and (B) liabilities
not required to be reflected in the Company&rsquo;s financial statements pursuant to GAAP or disclosed in filings made with the Commission,
(iii) the Company has not altered its method of accounting, (iv) the Company has not declared or made any dividend or distribution of
cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital
stock and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company
stock option plans. The Company does not have pending before the Commission any request for confidential treatment of information. Except
for the issuance of the Securities contemplated by this Agreement, no event, liability, fact, circumstance, occurrence or development
has occurred or exists or is reasonably expected to occur or exist with respect to the Company or its Subsidiaries or their respective
businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under
applicable securities laws at the time this representation is made or deemed made that has not been publicly disclosed at least one Trading
Day prior to the date that this representation is made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(j) <U>Litigation</U>.
There is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened
against or affecting the Company, any Subsidiary or any of their respective properties before or by any court, arbitrator, governmental
or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &ldquo;<U>Action</U>&rdquo;).
Neither the Company nor any Subsidiary, nor to the knowledge of the Company, any director or officer thereof, is or has been the subject
of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary
duty. There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission
involving the Company or any current or former director or officer of the Company. The Commission has not issued any stop order or other
order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the
Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(k) <U>Labor Relations</U>.
No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could
reasonably be expected to result in a Material Adverse Effect. None of the Company&rsquo;s or its Subsidiaries&rsquo; employees is a member
of a union that relates to such employee&rsquo;s relationship with the Company or such Subsidiary, and neither the Company nor any of
its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships
with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected
to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement
or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued
employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any
of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and
regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the
failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(l) <U>Compliance</U>.
Neither the Company nor any Subsidiary: (i) is in default under or in violation of (and no event has occurred that has not been waived
that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or
any Subsidiary received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or credit agreement
or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default
or violation has been waived), (ii) is in violation of any judgment, decree or order of any court, arbitrator or other governmental authority
or (iii) is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality
and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result in a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(m) <U>Environmental
Laws</U>. The Company and its Subsidiaries (i) are in compliance with all federal, state, local and foreign laws relating to pollution
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata),
including laws relating to emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or
hazardous substances or wastes (collectively, &ldquo;<U>Hazardous Materials</U>&rdquo;) into the environment, or otherwise relating to
the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as
all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits,
plans or regulations, issued, entered, promulgated or approved thereunder (&ldquo;<U>Environmental Laws</U>&rdquo;); (ii) have received
all permits licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and
(iii) are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i), (ii) and (iii),
the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(n) <U>Regulatory
Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except
where the failure to possess such permits could not reasonably be expected to result in a Material Adverse Effect (&ldquo;<U>Material
Permits</U>&rdquo;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification
of any Material Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(o) <U>Title to Assets</U>.
The Company and the Subsidiaries have good and marketable title in fee simple to all real property owned by them and good and marketable
title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and
clear of all Liens, except for (i) Liens as do not materially affect the value of such property and do not materially interfere with the
use made and proposed to be made of such property by the Company and the Subsidiaries and (ii) Liens for the payment of federal, state
or other taxes, for which appropriate reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent
nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under
valid, subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(p) <U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to
so have would reasonably be expected to result in a Material Adverse Effect (collectively, the &ldquo;<U>Intellectual Property Rights</U>&rdquo;).
Other than as set forth in the SEC Reports, none of, and neither the Company nor any Subsidiary has received a notice (written or otherwise)
that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is expected to expire or terminate or be abandoned,
within two (2) years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest
audited financial statements included within the SEC Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual
Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material
Adverse Effect. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing infringement
by another Person of any of the Intellectual Property Rights. The Company and its Subsidiaries have taken reasonable security measures
to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(q) <U>Insurance</U>.
The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such
amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited
to, directors and officers insurance coverage. Neither the Company nor any Subsidiary has any reason to believe that it will not be able
to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may
be necessary to continue its business without a significant increase in cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(r) <U>Transactions
With Affiliates and Employees</U>. None of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company,
none of the employees of the Company or any Subsidiary is presently a party to any transaction with the Company or any Subsidiary (other
than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, providing for the borrowing of money from or lending
of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder,
member or partner, in each case in excess of $120,000 other than for (i) payment of salary or consulting fees for services rendered, (ii)
reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements under
any stock option plan of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(s) <U>Sarbanes-Oxley;
Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all applicable requirements of the Sarbanes-Oxley
Act of 2002, as amended, that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the
Commission thereunder that are effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a
system of internal accounting controls with the goal of providing reasonable assurance that: (i) transactions are executed in accordance
with management&rsquo;s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management&rsquo;s
general or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the Company and the Subsidiaries and designed such
disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits
under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&rsquo;s rules
and forms. The Company&rsquo;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company
and the Subsidiaries as of the end of the period covered by the most recently filed periodic report under the Exchange Act (such date,
the &ldquo;<U>Evaluation Date</U>&rdquo;). The Company presented in its most recently filed periodic report under the Exchange Act the
conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as
of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as such
term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially
affect, the internal control over financial reporting of the Company and its Subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(t) <U>Certain Fees</U>.
Except for fees payable by the Company to the Placement Agent, no brokerage or finder&rsquo;s fees or commissions are or will be payable
by the Company or any Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other
Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with respect
to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may
be due in connection with the transactions contemplated by the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(u) <U>Investment Company</U>.
The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Securities, will not be or be an Affiliate
of, an &ldquo;investment company&rdquo; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct
its business in a manner so that it will not become an &ldquo;investment company&rdquo; subject to registration under the Investment Company
Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(v) <U>Registration
Rights</U>. Other than the selling securityholder included in the Registration Statement, no Person has any right to cause the Company
or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(w) <U>Listing and Maintenance
Requirements</U>. The Common Stock is registered pursuant to Section 12(b) or 12(g) of the Exchange Act, and the Company has taken no
action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under
the Exchange Act nor has the Company received any notification that the Commission is contemplating terminating such registration. Except
as set forth in the SEC Reports, the Company has not, in the 12 months preceding the date hereof, received notice from any Trading Market
on which the Common Stock is or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance
requirements of such Trading Market. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company
or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust Company (or such
other established clearing corporation) in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(x) <U>Application of
Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under the Company&rsquo;s certificate of incorporation (or similar charter documents) or the laws of its state
of incorporation that is or could become applicable to the Purchasers as a result of the Purchasers and the Company fulfilling their obligations
or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&rsquo;s issuance of
the Securities and the Purchasers&rsquo; ownership of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(y) <U>Disclosure</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, the Company confirms
that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information
that it believes constitutes or might constitute material, non-public information which is not otherwise disclosed in the Prospectus Supplement.
The Company understands and confirms that the Purchasers will rely on the foregoing representation in effecting transactions in securities
of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries,
their respective businesses and the transactions contemplated hereby is true and correct and does not contain any untrue statement of
a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances
under which they were made, not misleading. The Company acknowledges and agrees that no Purchaser makes or has made any representations
or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section 3.2 hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(z) <U>No Integrated
Offering</U>. Assuming the accuracy of the Purchasers&rsquo; representations and warranties set forth in Section 3.2, neither the Company,
nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security
or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with
prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the
securities of the Company are listed or designated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(aa) <U>[RESERVED]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(bb) <U>Tax Status</U>.
Except for matters that would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect,
the Company and its Subsidiaries each (i) has made or filed all United States federal, state and local income and all foreign income and
franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii) has paid all taxes and other
governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations
and (iii) has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the
periods to which such returns, reports or declarations apply. There are no unpaid taxes in any material amount claimed to be due by the
taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(cc) <U>Foreign Corrupt
Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any Subsidiary, any agent or other person
acting on behalf of the Company or any Subsidiary, has (i) directly or indirectly, used any funds for unlawful contributions, gifts, entertainment
or other unlawful expenses related to foreign or domestic political activity, (ii) made any unlawful payment to foreign or domestic government
officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii) failed to disclose fully
any contribution made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which
is in violation of law, or (iv) violated in any material respect any provision of FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(dd) <U>Accountants</U>.
To the knowledge and belief of the Company, the Company&rsquo;s accounting firm (i) is a registered public accounting firm as required
by the Exchange Act and (ii) shall express its opinion with respect to the financial statements to be included in the Company&rsquo;s
Annual Report for the fiscal year ending March 31, 2026 (or such other fiscal year end then applicable to the Company).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ee) <U>Acknowledgment
Regarding Purchasers&rsquo; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely
in the capacity of an arm&rsquo;s length purchaser with respect to the Transaction Documents and the transactions contemplated thereby.
The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity)
with respect to the Transaction Documents and the transactions contemplated thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely
incidental to the Purchasers&rsquo; purchase of the Securities. The Company further represents to each Purchaser that the Company&rsquo;s
decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions
contemplated hereby by the Company and its representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ff) <U>Acknowledgment
Regarding Purchaser&rsquo;s Trading Activity</U>. Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except
for Section 4.14 hereof), it is understood and acknowledged by the Company that: (i) none of the Purchasers has been asked by the Company
to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &ldquo;derivative&rdquo;
securities based on securities issued by the Company or to hold the Securities for any specified term; (ii) past or future open market
or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &ldquo;derivative&rdquo; transactions,
before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company&rsquo;s
publicly-traded securities; (iii) any Purchaser, and counter-parties in &ldquo;derivative&rdquo; transactions to which any such Purchaser
is a party, directly or indirectly, presently may have a &ldquo;short&rdquo; position in the Common Stock, and (iv) each Purchaser shall
not be deemed to have any affiliation with or control over any arm&rsquo;s length counter-party in any &ldquo;derivative&rdquo; transaction.
The Company further understands and acknowledges that (y) one or more Purchasers may engage in hedging activities at various times during
the period that the Securities are outstanding, including, without limitation, during the periods that the value of the Common Warrant
Shares deliverable with respect to Securities are being determined, and (z) such hedging activities (if any) could reduce the value of
the existing stockholders&rsquo; equity interests in the Company at and after the time that the hedging activities are being conducted.
The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(gg) <U>Regulation M
Compliance</U>. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken, directly or indirectly, any action
designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of any of the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases of, any of the Securities,
or (iii) paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company,
other than, in the case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(hh) <U>FDA</U>. As
to each product subject to the jurisdiction of the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) under the Federal Food,
Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<U>FDCA</U>&rdquo;) that is manufactured, packaged, labeled,
tested, distributed, sold, and/or marketed by the Company or any of its Subsidiaries (each such product, a &ldquo;<U>Product</U>&rdquo;),
such Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all
applicable requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance,
licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices, product listing,
quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material
Adverse Effect. There is no pending, completed or, to the Company&rsquo;s knowledge, threatened, action (including any lawsuit, arbitration,
or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries,
and none of the Company or any of its Subsidiaries has received any notice, warning letter or other communication from the FDA or any
other governmental entity, which (i) contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution
of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any Product, (ii) withdraws its approval
of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or sales promotional materials
relating to, any Product, (iii) imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv)
enjoins production at any facility of the Company or any of its Subsidiaries, (v) enters or proposes to enter into a consent decree of
permanent injunction with the Company or any of its Subsidiaries, or (vi) otherwise alleges any violation of any laws, rules or regulations
by the Company or any of its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The
properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all applicable
laws, rules and regulations of the FDA. The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license
or use in the United States of any product proposed to be developed, produced or marketed by the Company nor has the FDA expressed any
concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ii) <U>Stock Option
Plans</U>. Each stock option granted by the Company under the Company&rsquo;s stock option plan was granted (i) in accordance with the
terms of the Company&rsquo;s stock option plan and (ii) with an exercise price at least equal to the fair market value of the Common Stock
on the date such stock option would be considered granted under GAAP and applicable law. No stock option granted under the Company&rsquo;s
stock option plan has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice
to knowingly grant, stock options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public
announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(jj) <U>Cybersecurity</U>.
Except as would not reasonably be expected to result in a Material Adverse Event, (i)(x) there has been no security breach or other compromise
of or relating to any of the Company&rsquo;s or any Subsidiary&rsquo;s information technology and computer systems, networks, hardware,
software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or
on behalf of it), equipment or technology (collectively, &ldquo;<U>IT Systems and Data</U>&rdquo;) and (y) other than as disclosed in
the SEC Reports, the Company and the Subsidiaries have not been notified of, and has no knowledge of any event or condition that would
reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii) the Company and the Subsidiaries
are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems
and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as
would not, individually or in the aggregate, have a Material Adverse Effect; (iii) the Company and the Subsidiaries have implemented and
maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and Data; and (iv) the Company and the Subsidiaries have implemented backup and disaster
recovery technology consistent with industry standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(kk) <U>Office of Foreign
Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&rsquo;s knowledge, any director, officer, agent, employee
or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(ll) <U>U.S. Real Property
Holding Corporation</U>. The Company is not and has never been a U.S. real property holding corporation within the meaning of Section
897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&rsquo;s request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(mm) <U>Bank Holding
Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank Holding Company Act of 1956, as
amended (the &ldquo;<U>BHCA</U>&rdquo;) and to regulation by the Board of Governors of the Federal Reserve System (the &ldquo;<U>Federal
Reserve</U>&rdquo;). Neither the Company nor any of its Subsidiaries or Affiliates owns or controls, directly or indirectly, five percent
(5%) or more of the outstanding shares of any class of voting securities or twenty-five percent or more of the total equity of a bank
or any entity that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to
regulation by the Federal Reserve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(nn) <U>Money Laundering</U>.
The operations of the Company and its Subsidiaries are and have been conducted at all times in compliance in all material respects with
applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended,
applicable money laundering statutes and applicable rules and regulations thereunder (collectively, the &ldquo;<U>Money Laundering Laws</U>&rdquo;),
and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or
any Subsidiary with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(oo) <U>Other Covered
Persons</U>. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person) that has been
or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(pp) <U>Notice of Disqualification
Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of (i) any Disqualification Event relating to
any Issuer Covered Person and (ii) any event that would, with the passage of time, reasonably be expected to become a Disqualification
Event relating to any Issuer Covered Person, in each case of which it is aware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.2 <U>Representations and
Warranties of the Purchasers</U>. Each Purchaser, for itself and for no other Purchaser, hereby represents and warrants as of the date
hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate
as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(a) <U>Organization; Authority</U>.
Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws
of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power
and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its
obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the
transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability
company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly
executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally
binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable
principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement
of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief
or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(b) <U>Own Account</U>.
Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings
with any other persons to distribute or regarding the distribution of such Securities. Such Purchaser is acquiring the Securities hereunder
in the ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(c) <U>Experience of Such
Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in
business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(d) <U>Access to Information</U>.
Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules
thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has deemed necessary of, and to receive
answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and
risks of investing in the Securities all such questions, if any, have been answered to its satisfaction; (ii) access to information about
the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it
to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire
without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. Such
Purchaser acknowledges and agrees that neither the Placement Agent nor any Affiliate of the Placement Agent has provided such Purchaser
with any information or advice with respect to the Securities nor is such information or advice necessary or desired. Neither the Placement
Agent nor any Affiliate has made or makes any representation as to the Company or the quality of the Securities and the Placement Agent
and any Affiliate may have acquired non-public information with respect to the Company which such Purchaser agrees need not be provided
to it. In connection with the issuance of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has
acted as a financial advisor or fiduciary to such Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21pt; text-align: justify; text-indent: 51pt">(e) <U>Certain Transactions
and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting
on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short
Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received definitive pricing
terms (written or oral) from the Company or any other Person representing the Company setting forth the material pricing terms of the
transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of
a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions
of such Purchaser&rsquo;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by
the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons
party to this Agreement or to such Purchaser&rsquo;s representatives, including, without limitation, its officers, directors, partners,
legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made
to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for
the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect
to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company acknowledges and agrees that the representations
contained in this Section 3.2 shall not modify, amend or affect such Purchaser&rsquo;s right to rely on the Company&rsquo;s representations
and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other
document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated
hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty,
or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE IV.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">4.1 <U>Legends</U>. The Shares, Pre-Funded Warrants
and Common Warrants shall be issued free of legends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.2 <U>Furnishing of Information</U>.
Until the earlier of the time that (i) no Purchaser owns Securities or (ii) the Common Warrants have expired, the Company covenants to
timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by
the Company after the date hereof pursuant to the Exchange Act even if the Company is not then subject to the reporting requirements of
the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.3 <U>Integration</U>. The Company
shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of
the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would be integrated with the offer
or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval
prior to the closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.4 <U>Securities Laws Disclosure;
Publicity</U>. The Company shall (a) by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated
hereby, and (b) file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto, with the Commission within
the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that
it shall have publicly disclosed all material, non-public information delivered to any of the Purchasers by the Company or any of its
Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without limitation, the Placement
Agent, in connection with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such
press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether
written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or
agents, including, without limitation, the Placement Agent, on the one hand, and any of the Purchasers or any of their Affiliates on the
other hand, shall terminate and be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each
other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser
shall issue any such press release nor otherwise make any such public statement without the prior consent of the Company, with respect
to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company,
which consent shall not unreasonably be withheld or delayed, except if such disclosure is required by law, in which case the disclosing
party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing,
the Company shall not publicly disclose the name of any Purchaser, or include the name of any Purchaser in any filing with the Commission
or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a) as required by federal securities
law in connection with the filing of final Transaction Documents with the Commission and (b) to the extent such disclosure is required
by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such disclosure permitted
under this clause (b) and reasonably cooperate with such Purchaser regarding such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.5 <U>Shareholder Rights Plan</U>.
No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &ldquo;<U>Acquiring
Person</U>&rdquo; under any control share acquisition, business combination, poison pill (including any distribution under a rights agreement)
or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger
the provisions of any such plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement
between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.6 <U>Non-Public Information</U>.
Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents, which shall be
disclosed pursuant to Section 4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide
any Purchaser or its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material
non-public information, unless prior thereto such Purchaser shall have consented in writing to the receipt of such information and agreed
in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying
on the foregoing covenant in effecting transactions in securities of the Company. To the extent that the Company, any of its Subsidiaries,
or any of their respective officers, directors, agents, employees or Affiliates delivers any material, non-public information to a Purchaser
without such Purchaser&rsquo;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality
to the Company, any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, including, without
limitation, the Placement Agent, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees,
Affiliates or agents, including, without limitation, the Placement Agent, not to trade on the basis of, such material, non-public information,
provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction
Document constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously
with the delivery of such notice file such notice with the Commission pursuant to a Current Report on Form 8-K. The Company understands
and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.7 <U>Use of Proceeds</U>. The
Company shall use the net proceeds from the sale of the Securities hereunder in the manner set forth in the Prospectus, and shall not
use such proceeds: (a) for the satisfaction of any portion of the Company&rsquo;s debt (other than payment of trade payables and accrued
liabilities in the ordinary course of the Company&rsquo;s business and prior practices), (b) for the redemption of any Common Stock or
Common Stock Equivalents, (c) for the settlement of any outstanding litigation or (d) in violation of FCPA or OFAC regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.8 <U>Indemnification of
Purchasers</U>. Subject to the provisions of this Section 4.8, the Company will indemnify and hold each Purchaser and its directors, officers,
shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such
titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser (within the meaning of Section
15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or
employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title
or any other title) of such controlling persons (each, a &ldquo;<U>Purchaser Party</U>&rdquo;) harmless from any and all losses, liabilities,
obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and
reasonable attorneys&rsquo; fees and costs of investigation that any such Purchaser Party may suffer or incur as a result of or relating
to (a) any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other
Transaction Documents or (b) any action instituted against the Purchaser Parties in any capacity (including a Purchaser Party&rsquo;s
status as an investor), or any of them or their respective Affiliates, by the Company or any stockholder of the Company who is not an
Affiliate of such Purchaser Party, arising out of or relating to any of the transactions contemplated by the Transaction Documents. For
the avoidance of doubt, the indemnification provided herein is intended to, and shall also cover, direct claims brought by the Company
against the Purchaser Parties; provided, however, that such indemnification shall not cover any loss, claim, damage or liability to the
extent it is finally judicially determined to be attributable to any Purchaser Party&rsquo;s breach of any of the representations, warranties,
covenants or agreements made by such Purchaser Party in any Transaction Document or any conduct by a Purchaser Party which is finally
judicially determined to constitute fraud, gross negligence or willful misconduct. If any action shall be brought against any Purchaser
Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in
writing, and, except with respect to direct claims brought by the Company, the Company shall have the right to assume the defense thereof
with counsel of its own choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate
counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of
such Purchaser Party except to the extent that (i) the employment thereof has been specifically authorized by the Company in writing,
(ii) the Company has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there
is, in the reasonable opinion of counsel to the applicable Purchaser Party (which may be internal counsel), a material conflict on any
material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible
for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party
under this Agreement for any settlement by a Purchaser Party effected without the Company&rsquo;s prior written consent, which shall not
be unreasonably withheld or delayed. In addition, if any Purchaser Party takes actions to collect amounts due under any Transaction Documents
or to enforce the provisions of any Transaction Documents, then the Company shall pay the costs incurred by such Purchaser Party for such
collection, enforcement or action, including, but not limited to, attorneys&rsquo; fees and disbursements. The indemnification and other
payment obligations required by this Section 4.8 shall be made by periodic payments of the amount thereof during the course of the investigation,
defense, collection, enforcement or action, as and when bills are reasonably incurred and received; provided, that if any Purchaser Party
is finally judicially determined not to be entitled to indemnification or payment under this Section 4.8, such Purchaser Party shall promptly
reimburse the Company for any payments that are advanced under this sentence. The indemnity agreements contained herein shall be in addition
to any cause of action or similar right of any Purchaser Party against the Company or others and any liabilities the Company may be subject
to pursuant to law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.9 <U>Reservation of Common Stock</U>.
As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive
rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Shares pursuant to this Agreement
and Pre-Funded Warrant Shares pursuant to any exercise of the Pre-Funded Warrants. The Company shall reserve and keep available at all
times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue the Common
Warrant Shares pursuant to any exercise of the Common Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.10 <U>Listing of Common
Stock</U>. For as long as any Common Warrants are outstanding and exercisable, the Company hereby agrees to use reasonable best efforts
to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with
the Closing, the Company shall apply to list or quote all of the Shares, the Pre-Funded Warrant Shares and the Common Warrant Shares on
such Trading Market and promptly secure the listing of all of the Shares, the Pre-Funded Warrant Shares and the Common Warrant Shares
on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market,
it will then include in such application all of the Shares, the Pre-Funded Warrant Shares and the Common Warrant Shares, and will take
such other action as is necessary to cause all of the Shares, the Pre-Funded Warrant Shares and the Common Warrant Shares to be listed
or quoted on such other Trading Market as promptly as possible. The Company will then take all action reasonably necessary to continue
the listing and trading of its Common Stock on a Trading Market and will comply in all material respects with the Company&rsquo;s reporting,
filing and other obligations under the bylaws or rules of the Trading Market. For so long as the Company maintains a listing or quotation
of the Common Stock on a Trading Market, the Company agrees to maintain the eligibility of the Common Stock for electronic transfer through
the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to
the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.11 <U>Subsequent Equity Sales</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(a) From the date hereof
until ninety (90) days after the date hereof, neither the Company nor any Subsidiary shall issue, enter into any agreement to issue or
announce the issuance or proposed issuance of any shares of Common Stock or Common Stock Equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(b) From the date hereof
until one (1) year after the Closing Date, the Company shall be prohibited from effecting or entering into an agreement to effect any
issuance by the Company or any of its Subsidiaries of Common Stock or Common Stock Equivalents (or a combination of units thereof) involving
a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company (i) issues or sells
any debt or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares
of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with,
the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities
or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of
such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of
the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not
limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the Company may issue securities at a future
determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement
is subsequently canceled; <U>provided</U>, <U>however</U>, that, after ninety (90) days following the Closing Date, the issuance of shares
of Common Stock in an &ldquo;at the market&rdquo; offering with H.C. Wainwright &amp; Co., LLC as sales agent shall not be deemed a Variable
Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which
remedy shall be in addition to any right to collect damages. Any Purchaser shall be entitled to obtain injunctive relief against the Company
to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in">(c) Notwithstanding
the foregoing, this Section 4.11 shall not apply in respect of an Exempt Issuance, except that no Variable Rate Transaction shall be an
Exempt Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.12 <U>Equal Treatment of Purchasers</U>.
No consideration (including any modification of any Transaction Document) shall be offered or paid to any Person to amend or consent to
a waiver or modification of any provision of the Transaction Documents unless the same consideration is also offered to all of the parties
to the Transaction Documents. For clarification purposes, this provision constitutes a separate right granted to each Purchaser by the
Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not
in any way be construed as the Purchasers acting in concert or as a group with respect to the purchase, disposition or voting of Securities
or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.13 <U>Certain Transactions and
Confidentiality</U>. Each Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate
acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the
Company&rsquo;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions
contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4. Each Purchaser,
severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement
are publicly disclosed by the Company pursuant to the initial press release as described in Section 4.4, such Purchaser will maintain
the confidentiality of the existence and terms of this transaction (other than as disclosed to its legal and other representatives). Notwithstanding
the foregoing and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees
that (i) no Purchaser makes any representation, warranty or covenant hereby that it will not engage in effecting transactions in any securities
of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial
press release as described in Section 4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any
securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by
this Agreement are first publicly announced pursuant to the initial press release as described in Section 4.4 and (iii) no Purchaser shall
have any duty of confidentiality or duty not to trade in the securities of the Company to the Company, any of its Subsidiaries, or any
of their respective officers, directors, employees, Affiliates or agent, including, without limitation, the Placement Agent, after the
issuance of the initial press release as described in Section 4.4. Notwithstanding the foregoing, in the case of a Purchaser that is a
multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&rsquo;s assets and the
portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such
Purchaser&rsquo;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio
manager that made the investment decision to purchase the Securities covered by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.14 <U>Exercise Procedures</U>.
The form of Notice of Exercise included in the Pre-Funded Warrants and Common Warrants set forth the totality of the procedures required
of the Purchasers in order to exercise such Pre-Funded Warrants or Common Warrants, as applicable. No additional legal opinion, other
information or instructions shall be required of the Purchasers to exercise such Pre-Funded Warrants or Common Warrants. Without limiting
the preceding sentences, no ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee
or notarization) of any Notice of Exercise form be required in order to exercise such Pre-Funded Warrants or Common Warrants. The Company
shall honor exercises of such Pre-Funded Warrants or Common Warrants and shall deliver the Pre-Funded Warrant Shares or Common Warrant
Shares, as applicable, in accordance with the terms, conditions and time periods set forth in the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.15 <U>Lock-Up Agreements</U>.
The Company shall not amend, modify, waive or terminate any provision of any of the Lock-Up Agreements except to extend the term of the
lock-up period and shall enforce the provisions of each Lock-Up Agreement in accordance with its terms. If any party to a Lock-Up Agreement
breaches any provision of a Lock-Up Agreement, the Company shall promptly use its best efforts to seek specific performance of the terms
of such Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ARTICLE V.<BR>
</B>MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.1 <U>Termination</U>. This Agreement
may be terminated by any Purchaser, as to such Purchaser&rsquo;s obligations hereunder only and without any effect whatsoever on the obligations
between the Company and the other Purchasers, by written notice to the other parties, if the Closing has not been consummated on or before
the fifth (5<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>,
that no such termination will affect the right of any party to sue for any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.2 <U>Fees and Expenses</U>.
Except as expressly set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any
fees required for same-day processing of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser),
stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.3 <U>Entire Agreement</U>.
The Transaction Documents, together with the exhibits and schedules thereto, the Prospectus and the Prospectus Supplement, contain the
entire understanding of the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.4 <U>Notices</U>. Any and all
notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given
and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email attachment at the
email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b)
the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email address
as set forth on the signature pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on
any Trading Day, (c) the second (2<FONT STYLE="font-size: 10pt"><SUP>nd</SUP></FONT>) Trading Day following the date of mailing, if sent
by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such notice is required to be
given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.5 <U>Amendments; Waivers</U>.
No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in the case of
an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial Subscription
Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts
a Purchaser (or group of Purchasers), the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also be
required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing
waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall
any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right. Any proposed amendment
or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable
rights and obligations of the other Purchasers shall require the prior written consent of such adversely affected Purchaser. Any amendment
effected in accordance with this Section 5.5 shall be binding upon each Purchaser and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.6 <U>Headings</U>. The headings
herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.7 <U>Successors and Assigns</U>.
This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. The Company may
not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger).
Any Purchaser may assign any or all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities,
provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the Transaction
Documents that apply to the &ldquo;Purchasers.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.8 <U>No Third-Party Beneficiaries</U>.
The Placement Agent shall be a third party beneficiary of the representations and warranties of the Company in Section 3.1 and the representations
and warranties of the Purchasers in Section 3.2. This Agreement is intended for the benefit of the parties hereto and their respective
successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except
as otherwise set forth in Section 4.8 and this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.9 <U>Governing Law</U>. All
questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal Proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party hereby irrevocably waives
personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered
or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall commence an Action
or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section
4.8, the prevailing party in such Action or Proceeding shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo;
fees and other costs and expenses incurred with the investigation, preparation and prosecution of such Action or Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.10 <U>Survival</U>. The representations
and warranties contained herein shall survive the Closing and the delivery of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.11 <U>Execution</U>. This Agreement
may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties
need not sign the same counterpart. In the event that any signature is delivered by e-mail delivery of a &ldquo;.pdf&rdquo; format data
file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such &ldquo;.pdf&rdquo; signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.12 <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.13 <U>Rescission and Withdrawal
Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of) any of the other Transaction
Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not
timely perform its related obligations within the periods therein provided, then such Purchaser may rescind or withdraw, in its sole discretion
from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to
its future actions and rights; <U>provided</U>, <U>however</U>, that in the case of a rescission of an exercise of a Pre-Funded Warrant
or Common Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise
notice concurrently with the return to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration
of such Purchaser&rsquo;s right to acquire such shares pursuant to such Purchaser&rsquo;s Pre-Funded Warrant or Common Warrant (including,
issuance of a replacement warrant certificate evidencing such restored right).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.14 <U>Replacement of Securities</U>.
If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to
be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor,
a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction.
The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including
customary indemnity) associated with the issuance of such replacement Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.15 <U>Remedies</U>. In addition
to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of the Purchasers and
the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not
be adequate compensation for any loss incurred by reason of any breach of obligations contained in the Transaction Documents and hereby
agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would
be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.16 <U>Payment Set Aside</U>.
To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document or a Purchaser enforces
or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are
subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be refunded,
repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any
bankruptcy law, state or federal law, common law or equitable cause of action), then to the extent of any such restoration the obligation
or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not
been made or such enforcement or setoff had not occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.17 <U>Independent Nature
of Purchasers&rsquo; Obligations and Rights</U>. The obligations of each Purchaser under any Transaction Document are several and not
joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance
of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document,
and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently
protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any Proceeding for such purpose.
Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. For
reasons of administrative convenience only, each Purchaser and its respective counsel have chosen to communicate with the Company through
Pryor Cashman LLP. Pryor Cashman LLP does not represent any of the Purchasers and only represents the Placement Agent. The Company has
elected to provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it
was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision contained in this
Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers
collectively and not between and among the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.18 <U>Saturdays, Sundays, Holidays,
etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not
be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.19 <U>Construction</U>. The
parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits,
stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.20 <B><U>WAIVER OF JURY TRIAL</U>.
IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY,
TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL
BY JURY.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the
parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>AETHLON MEDICAL, INC.</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%; font-size: 10pt">By:</TD>
    <TD STYLE="width: 46%; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Name:</TD>
    <TD STYLE="font-size: 10pt">James Frakes</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">Chief Executive Officer and Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Address for Notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">11555 Sorrento Valley Road, Suite 203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">San Diego, CA 92121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">E-Mail: jfrakes@aethlonmedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">With a copy to (which shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Procopio Cory Hargreaves &amp; Savitch, LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">12544 High Bluff Dr.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Suite 400</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">San Diego, CA 92130</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">E-mail: dennis.doucette@procopio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Attention: Dennis J. Doucette</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">[PURCHASER SIGNATURE PAGES TO AEMD SECURITIES
PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the undersigned
have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Purchaser: ________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Signature of Authorized Signatory of Purchaser</I>:
_________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Name of Authorized Signatory: _______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Title of Authorized Signatory: ________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Email Address of Authorized Signatory:_________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Principal Place of Business:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Address for Notice to Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Address for Delivery of Warrants to Purchaser (if not same as address for
notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Subscription Amount: $_________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Shares: _________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pre-Funded Warrant Shares: ___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Common Warrant Shares: __________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">EIN Number: _______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Form of Common Warrant</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Form of Lock-up Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><U>Form of Pre-Funded Warrant</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 30; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>6
<FILENAME>aethlon_ex1002.htm
<DESCRIPTION>PLACEMENT AGENCY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<IMG SRC="image_012.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">CONFIDENTIAL</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 388pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">September 4, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Mr. James B. Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Chief Executive
Officer and Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">11555 Sorrento
Valley Road, Suite 203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">San Diego, CA 92121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Dear Mr.
Frakes,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">This agreement
(the &ldquo;<U>Agreement</U>&rdquo;) constitutes the agreement between Aethlon Medical, Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;),
and Maxim Group LLC (&ldquo;<U>Maxim</U>&rdquo; or the &ldquo;<U>Lead Manager</U>&rdquo;), that Maxim shall serve as the exclusive lead
placement agent for the Company, on a &ldquo;reasonable best efforts&rdquo; basis (a &ldquo;<U>Placement</U>&rdquo;), in connection with
the proposed offerings of securities (the &ldquo;<U>Securities</U>&rdquo;) of the Company. The terms of such Placement and the Securities
shall be mutually agreed upon by the Company and the Lead Manager and, if a direct placement, the purchasers (each, a &ldquo;<U>Purchaser</U>&rdquo;
and collectively, the &ldquo;<U>Purchasers</U>&rdquo;) and nothing herein grants Maxim the power or authority to bind the Company or
any Purchaser or creates an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents
executed and delivered by the Company and the Purchasers in connection with the Placement shall be collectively referred to herein as
the &ldquo;<U>Transaction Documents</U>.&rdquo; The date of the closing of the Placement shall be referred to herein as the &ldquo;<U>Closing
Date</U>.&rdquo; The Company expressly acknowledges and agrees that Maxim&rsquo;s obligations hereunder are on a reasonable best efforts
basis only and that the execution of this Agreement does not constitute a commitment by Maxim to purchase the Securities and does not
ensure the successful placement of the Securities or any portion thereof or the success of Maxim with respect to securing any other financing
on behalf of the Company. Maxim may retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection
with the Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">The
sale of Securities to any Purchaser will be evidenced by a purchase agreement (&ldquo;<U>Purchase Agreement</U>&rdquo;) between the Company
and such Purchaser, if required by the Purchaser, in a form reasonably satisfactory to the Company and Maxim. Prior to the signing of
any Purchase Agreement, officers of the Company with responsibility for financial affairs will be reasonably available to answer inquiries
from prospective Purchasers. Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Purchase
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">Notwithstanding anything herein to the contrary, in the event that Maxim determines that any of the terms provided for hereunder
shall not comply with a FINRA rule, including, but not limited to, FINRA Rule 5110, then the Company shall agree to amend this Agreement
in writing upon the request of Maxim to comply with any such rules; provided that any such amendments shall not provide for terms that
are less favorable to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 4, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>SECTION 1.</U>&nbsp;&nbsp;&nbsp;<U>Compensation and other Fees.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">As compensation for the services provided by Maxim
hereunder, the Company agrees to pay to Maxim the fees set forth below with respect to the Placement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 27pt">(i)</TD><TD STYLE="text-align: justify; padding-right: 17.7pt">A cash fee payable immediately upon the closing of the Placement equal to six and
one- quarter percent (6.25%) of the aggregate gross proceeds raised in the Placement (the &ldquo;<U>Cash Fee</U>&rdquo;) on the Closing
Date from the sale of Securities.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 27pt">(ii)</TD><TD STYLE="text-align: justify; padding-right: 17.75pt">Subject to compliance with FINRA Rule 5110(f)(2)(D), the Company also agrees,
in case of a Closing of the Placement, to reimburse the Lead Manager for all reasonable and documented out-of-pocket expenses incurred,
including the reasonable fees, costs and disbursements of its legal counsel, in an amount not to exceed an aggregate of $100,000; <U>provided</U>,
however, that if the Placement is terminated, then such reimbursement shall not exceed an aggregate of $50,000. The Company will reimburse
Lead Manager directly upon the Closing of the Placement from the gross proceeds raised in the Placement.</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 27pt">(iii)</TD><TD STYLE="text-align: justify; padding-right: 17.6pt">Warrants to purchase up to 4% of the aggregate number of shares of common stock
issued in the Placement, with an exercise price of 100% of the combined public offering price per share of common stock (or pre-funded
warrant) and accompanying warrant in the offering. Pursuant to FINRA Rule 5110 (e)(1), such placement agent warrant will be non-exercisable,
and will therefore not be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative,
put or call transaction that would result in the effective economic disposition of such placement agent warrant, for a period of six (6)
months after the date of the Closing; <U>provided</U>, <U>however</U>, that the exceptions listed under FINRA Rule 5110(e)(2) shall apply.
Such placement agent warrant will expire five years after the commencement of sales of the offering.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION 2.</U>&nbsp;&nbsp;&nbsp;<U>RESERVED.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.65pt 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION 3.</U>&nbsp;&nbsp;&nbsp;<U>REPRESENTATIONS
AND WARRANTIES</U>. The Company makes to Maxim all of the representations and warranties which the Company makes to the Purchasers in
the Purchase Agreement, and in addition makes the following representation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>FINRA Affiliations</U>.
There are no affiliations with any FINRA member firm among the Company&rsquo;s officers, directors or, to the knowledge of the Company,
any five percent (5%) or greater stockholder of the Company, except as set forth in the Company&rsquo;s public filings under the Securities
Exchange Act of 1934, as amended, with the Securities and Exchange Commission (the &ldquo;<U>SEC Filings</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.75pt 0pt 0; text-align: justify; text-indent: 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION
4.</U>&nbsp;&nbsp;&nbsp; <U>REPRESENTATIONS OF MAXIM</U>. Maxim represents and warrants that it is (i) a member in good standing of FINRA,
(ii) registered as a broker/dealer under the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;), and (iii) licensed as
a broker/dealer under the laws of the States applicable to the offers and sales of Securities by Maxim. Maxim will immediately notify
the Company in writing of any change in its status as such. Maxim covenants that it will use its reasonable best efforts to conduct the
Transaction hereunder in compliance with the provisions of this Agreement and the requirements of applicable law. Except as required
by law or as contemplated by this agreement, Maxim will keep confidential all material nonpublic information, including information regarding
the Transaction contemplated hereunder, provided to it by the Company or its affiliates or advisors and use such information only for
the purposes contemplated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 4, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 3</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION 5.</U>&nbsp;&nbsp;&nbsp;<U>INDEMNIFICATION</U>. The Company agrees to the indemnification and other agreements set
forth in the Indemnification Provisions (the &ldquo;<U>Indemnification</U>&rdquo;) attached hereto as Addendum A, the provisions of which
are incorporated herein by reference and shall survive the termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION 6.</U>&nbsp;&nbsp;&nbsp;<U>ENGAGEMENT
TERM</U>. Maxim&rsquo;s engagement hereunder shall become effective on the date hereof and shall continue until the earlier of (a) the
Closing Date or (b) the date a party terminates the engagement according to the letter agreement entered into between the Company and
Maxim on July 16, 2025 (such date, the &ldquo;<U>Termination Date</U>&rdquo;). Notwithstanding anything to the contrary contained herein,
the provisions concerning confidentiality, indemnification, contribution and the Company&rsquo;s obligations to pay fees and reimburse
expenses earned or due prior to the termination of the Agreement contained herein and the Company&rsquo;s obligations contained in the
Indemnification Provisions will survive any expiration or termination of this Agreement. Maxim agrees not to use any confidential information
concerning the Company provided to Maxim by the Company for any purposes other than those contemplated under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION 7.</U>&nbsp;&nbsp;&nbsp;<U>SUBSEQUENT EQUITY SALES AND VARIABLE
RATE TRANSACTIONS</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 27pt">(i)</TD><TD STYLE="text-align: justify; padding-right: 17.55pt">From the date hereof until sixty (60) days after the date hereof, neither the
Company nor any Subsidiary shall issue, enter into any agreement to issue or announce the issuance or proposed issuance of any shares
of Common Stock or Common Stock Equivalents.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 54pt"></TD><TD STYLE="width: 27pt">(ii)</TD><TD STYLE="text-align: justify; padding-right: 17.65pt">From the date hereof until one (1) year after the Closing Date, the Company shall
be prohibited from effecting or entering into an agreement to effect any issuance by the Company or any of its Subsidiaries of Common
Stock or Common Stock Equivalents (or a combination of units thereof) involving a Variable Rate Transaction, without the prior written
consent of Maxim. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which the Company (i) issues or sells any debt
or equity securities that are convertible into, exchangeable or exercisable for, or include the right to receive additional shares of
Common Stock either (A) at a conversion price, exercise price or exchange rate or other price that is based upon, and/or varies with,
the trading prices of or quotations for the shares of Common Stock at any time after the initial issuance of such debt or equity securities
or (B) with a conversion, exercise or exchange price that is subject to being reset at some future date after the initial issuance of
such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the business of
the Company or the market for the Common Stock or (ii) enters into, or effects a transaction under, any agreement, including, but not
limited to, an equity line of credit or an &ldquo;at-the-market offering,&rdquo; whereby the Company may issue securities at a future
determined price regardless of whether shares pursuant to such agreement have actually been issued and regardless of whether such agreement
is subsequently canceled; <U>provided</U>, <U>however</U>, that, after sixty (60) days following the Closing Date, the issuance of shares
of Common Stock in an &ldquo;at the market&rdquo; offering with H.C. Wainwright &amp; Co., LLC as sales agent shall not be deemed a Variable
Rate Transaction. Any Purchaser shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which
remedy shall be in addition to any right to collect damages. Any Purchaser shall be entitled to obtain injunctive relief against the Company
to preclude any such issuance, which remedy shall be in addition to any right to collect damages.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION 8.</U>&nbsp;&nbsp;&nbsp;<U>LEAD
MANAGER INFORMATION.</U> The Company agrees that any information or advice rendered by Maxim in connection with this engagement is for
the confidential use of the Company only in their evaluation of the Placement and, except as otherwise required by law, the Company will
not disclose or otherwise refer to the advice or information in any manner without Maxim&rsquo;s prior written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 4, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 4</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION 9.</U>&nbsp;&nbsp;&nbsp;<U>NO
FIDUCIARY RELATIONSHIP.</U> This Agreement does not create, and shall not be construed as creating rights enforceable by any person or
entity not a party hereto, except those entitled hereto by virtue of the Indemnification Provisions hereof. The Company acknowledges and
agrees that Maxim is and shall not be construed to be a fiduciary of the Company and shall have no duties or liabilities to the equity
holders or the creditors of the Company or any other person by virtue of this Agreement or the retention of Maxim hereunder, all of which
are hereby expressly waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION 10.</U>&nbsp;&nbsp;&nbsp;<U>CLOSING.</U>
The obligations of Maxim and the closing of the sale of the Securities hereunder are subject to the accuracy, when made and on the Closing
Date, of the representations and warranties on the part of the Company and its Subsidiaries contained herein, to the accuracy of the statements
of the Company and its Subsidiaries made in any certificates pursuant to the provisions hereof, to the performance by the Company and
its Subsidiaries of their obligations hereunder, and to each of the following additional terms and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(A)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>All corporate proceedings and other legal matters incident to the authorization, form, execution, delivery and validity of each
of this Agreement, the Securities, and all other legal matters relating to this Agreement and the transactions contemplated hereby shall
be reasonably satisfactory in all material respects to Maxim, and the Company shall have furnished to such counsel all documents and information
that they may reasonably request to enable them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(B)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Maxim shall have received from outside counsel to the Company such counsel&rsquo;s written opinion, addressed to Maxim and dated
as of the Closing Date, in form and substance reasonably satisfactory to Maxim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(C)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Neither the Company nor any of its Subsidiaries (i) shall have sustained since the date of the latest audited financial statements
of the Company included in the SEC Filings, any loss or interference with its business from fire, explosion, flood, terrorist act or other
calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than
as set forth in or contemplated by the SEC Filings, and (ii) since such date there shall not have been any change in the capital stock
or long-term debt of the Company or any of its subsidiaries or any change, or any development involving a prospective change, in or affecting
the business, general affairs, management, financial position, stockholders&rsquo; equity, results of operations or prospects of the Company
and its subsidiaries, otherwise than as set forth in or contemplated by the SEC Filings, the effect of which, in any such case described
in clause (i) or (ii), is, in the judgment of Maxim, so material and adverse as to make it impracticable or inadvisable to proceed with
the sale or delivery of the Securities on the terms and in the manner contemplated by the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(D) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The common stock of the Company is registered under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(E)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any governmental
agency or body which would, as of the Closing Date, prevent the issuance or sale of the Securities or materially and adversely affect
or potentially and adversely affect the business or operations of the Company; and no injunction, restraining order or order of any other
nature by any federal or state court of competent jurisdiction shall have been issued as of the Closing Date which would prevent the issuance
or sale of the Securities or materially and adversely affect or potentially and adversely affect the business or operations of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(F)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company shall have prepared and filed with the Commission a Current Report on Form 8-K with respect to the Placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(G)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company shall have entered into Purchase Agreements with each of the Purchasers and such agreements shall be in full force
and effect and shall contain representations and warranties of the Company as agreed between the Company and the Purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">(H)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Prior to the Closing Date, the Company shall have furnished to Maxim such further information, certificates and documents as Maxim
may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 4, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION 11</U>.&nbsp;&nbsp;&nbsp;<U>GOVERNING LAW.</U> This Agreement will be governed by, and construed in accordance with, the laws of the State of New York applicable
to agreements made and to be performed entirely in such State. This Agreement may not be assigned by either party without the prior written
consent of the other party. This Agreement shall be binding upon and inure to the benefit of the parties hereto, and their respective
successors and permitted assigns. Any right to trial by jury with respect to any dispute arising under this Agreement or any transaction
or conduct in connection herewith is waived. Any dispute arising under this Agreement may be brought into the courts of the State of New
York or into the Federal Court located in New York, New York and, by execution and delivery of this Agreement, the Company hereby accepts
for itself and in respect of its property, generally and unconditionally, the jurisdiction of aforesaid courts. Each party hereto hereby
irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by delivering
a copy thereof via overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this
Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein
shall be deemed to limit in any way any right to serve process in any manner permitted by law. If either party shall commence an action
or proceeding to enforce any provisions of a Transaction Document, then the prevailing party in such action or proceeding shall be reimbursed
by the other party for its attorney&rsquo;s fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION 12</U>.
&nbsp;&nbsp;&nbsp;<U>ENTIRE AGREEMENT/MISCELLANEOUS</U>. This Agreement (including the attached Indemnification Provisions) embodies the entire agreement
and understanding between the parties hereto and supersedes all prior agreements and understandings relating to the subject matter hereof,
other than that certain engagement letter entered into between the Company and Maxim, dated July 16, 2025. If any provision of this Agreement
is determined to be invalid or unenforceable in any respect, such determination will not affect such provision in any other respect or
any other provision of this Agreement, which will remain in full force and effect. This Agreement may not be amended or otherwise modified
or waived except by an instrument in writing signed by Maxim and the Company. The representations, warranties, agreements and covenants
contained herein shall survive the closing of the Placement and delivery and/or exercise of the Securities, as applicable. This Agreement
may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties
need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or a &ldquo;.pdf&rdquo; format
file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
with the same force and effect as if such facsimile signature page were an original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION
13</U>. &nbsp;&nbsp;&nbsp;<U>CONFIDENTIALITY</U>. Maxim (i) will keep the Confidential Information (as such term is defined below)
confidential and will not (except as required by applicable law or stock exchange requirement, regulation or legal process), without
the Company&rsquo;s prior written consent, disclose to any person any Confidential Information, and (ii) will not use any
Confidential Information other than in connection with its evaluation of the Transaction. Maxim further agrees to disclose the
Confidential Information only to its Representatives who need to know the Confidential Information for the purpose of evaluating the
Transaction, and who are informed by Maxim of the confidential nature of the Confidential Information. The term
&ldquo;<U>Confidential Information</U>&rdquo; shall mean, all confidential, proprietary and non-public information (whether written,
oral or electronic communications) furnished by the Company to Maxim or its Representatives in connection with Maxim&rsquo;s
evaluation of the Transaction. The term &ldquo;<U>Confidential Information</U>&rdquo; will not, however, include information which
(i) is or becomes publicly available other than as a result of a disclosure by Maxim or its Representatives in violation of this
Agreement, (ii) is or becomes available to Maxim or any of its Representatives on a nonconfidential basis from a third-party, (iii)
is known to Maxim or any of its Representatives prior to disclosure by the Company or any of its Representatives, (iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp; </FONT>is
or has been independently developed by Maxim and/or the Representatives without use of any Confidential Information furnished to it
by the Company, or (v) is required to be disclosed pursuant to applicable legal or regulatory authority. The term
&ldquo;Representatives&rdquo; shall mean a party's directors, board committees, officers, employees, financial advisors, attorneys
and accountants. This provision shall be in full force until the earlier of (a) the date that the Confidential Information ceases to
be confidential and (b) two years from the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 4, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 6</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><U>SECTION 14</U>.
&nbsp;&nbsp;&nbsp;<U>NOTICES.</U> Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing
and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via facsimile at the facsimile number specified on the signature pages attached hereto prior to 6:30 p.m. (New York City time) on a business
day, (b) the next business day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile
number on the signature pages attached hereto on a day that is not a business day or later than 6:30 p.m. (New York City time) on any
business day, (c) the business day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or
(d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall
be as set forth on the signature pages hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 17.9pt 0pt 0; text-align: center"><B><I>[Signature page follows]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 4, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P>We are excited about this equity offering and look forward to working with you. Please confirm that the foregoing correctly sets forth
our agreement by signing and returning the enclosed copy of this Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="padding-left: 20pt"><B>MAXIM GROUP LLC</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="padding-left: 20pt">By: <U>/s/ Ritesh Veera&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="padding-left: 40pt">Ritesh Veera</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="padding-left: 40pt">Co-Head of Investment Banking</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><U>Address for notice:</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>300 Park Avenue</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>16th Floor</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>New York, NY 10022</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 274.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 123.95pt 0pt 234.2pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Accepted and Agreed to as of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">the date first written above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">AETHLON MEDICAL, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">By: <U>/s/ James B. Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Name: James B. Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin-top: 0pt; margin-bottom: 0pt">Title: Chief Executive
Officer and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Address for notice:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11555 Sorrento Valley Road, Suite 203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego,
CA 92121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 4, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 8</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><U>ADDENDUM</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>INDEMNIFICATION PROVISIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">In connection with the engagement
of Maxim Group LLC (&ldquo;<U>Maxim</U>&rdquo;) by Aethlon Medical, Inc. (the &ldquo;<U>Company</U>&rdquo;) pursuant to this Agreement,
the Company hereby agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">To the extent permitted by law, the Company will indemnify Maxim and each of its
affiliates, directors, officers, employees and controlling persons (within the meaning of Section 15 of the Securities Act of 1933, as
amended, or Section 20 of the Securities Exchange Act of 1934, as amended) against all losses, claims, damages, expenses and liabilities,
as the same are incurred (including the reasonable fees and expenses of counsel), relating to or arising out of its activities hereunder
or pursuant to the Agreement, except, with regard to Maxim, to the extent that any losses, claims, damages, expenses or liabilities (or
actions in respect thereof) are found in a final judgment (not subject to appeal) by a court of law to have resulted primarily and directly
from Maxim&rsquo;s willful misconduct or gross negligence in performing the services described herein, as the case may be.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">Promptly after receipt by Maxim of notice of any claim or the commencement of
any action or proceeding with respect to which Maxim is entitled to indemnity hereunder, Maxim will notify the Company in writing of such
claim or of the commencement of such action or proceeding, and the Company will assume the defense of such action or proceeding and will
employ counsel reasonably satisfactory to Maxim and will pay the fees and expenses of such counsel. Notwithstanding the preceding sentence,
Maxim will be entitled to employ counsel separate from counsel for the Company and from any other party in such action if counsel for
Maxim reasonably determines that it would be inappropriate under the applicable rules of professional responsibility for the same counsel
to represent both the Company and Maxim. In such event, the reasonable fees and disbursements of no more than one such separate counsel
will be paid by the Company. The Company will have the exclusive right to settle the claim or proceeding provided that the Company will
not settle any such claim, action or proceeding without the prior written consent of Maxim, which will not be unreasonably withheld, unless
such settlement (x) includes an unconditional release of Maxim from all liability on claims that are the subject matter of such proceeding
and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of Maxim.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">The Company agrees to notify Maxim promptly of the assertion against it or any
other person of any claim or the commencement of any action or proceeding relating to a transaction contemplated by the Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">If for any reason the foregoing indemnity is unavailable to Maxim or insufficient
to hold Maxim harmless, then the Company shall contribute to the amount paid or payable by Maxim, as the case may be, as a result of such
losses, claims, damages or liabilities in such proportion as is appropriate to reflect not only the relative benefits received by the
Company on the one hand, and Maxim on the other, but also the relative fault of the Company on the one hand and Maxim on the other that
resulted in such losses, claims, damages or liabilities, as well as any relevant equitable considerations. The amounts paid or payable
by a party in respect of losses, claims, damages and liabilities referred to above shall be deemed to include any legal or other fees
and expenses incurred in defending any litigation, proceeding or other action or claim. Notwithstanding the provisions hereof, Maxim&rsquo;s
share of the liability hereunder shall not be in excess of the amount of fees actually received, or to be received, by Maxim under the
Agreement (excluding any amounts received as reimbursement of expenses incurred by Maxim).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 4, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 9</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 17.95pt"></TD><TD STYLE="width: 18.45pt">5.</TD><TD STYLE="text-align: justify">These Indemnification Provisions shall remain in full force and effect whether
or not the transaction contemplated by the Agreement is completed and shall survive the termination of the Agreement, and shall be in
addition to any liability that the Company might otherwise have to any indemnified party under the Agreement or otherwise.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 50%">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="padding-left: 20pt"><B>MAXIM GROUP LLC</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="padding-left: 20pt">By: <U>/s/ Larry Glassberg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="padding-left: 40pt">Larry Glassberg</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="padding-left: 40pt">Co-Head of Investment Banking</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD><U>Address for notice:</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>300 Park Avenue</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>16th Floor</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>New York, NY 10022</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 274.8pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 123.95pt 0pt 234.2pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">Accepted and Agreed to as of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">the date first written above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">AETHLON MEDICAL, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">By: <U>/s/ James B. Frakes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin-top: 0pt; margin-bottom: 0pt">Name: James B. Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 20pt; margin-top: 0pt; margin-bottom: 0pt">Title: Chief Executive
Officer and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 40pt; margin-top: 0pt; margin-bottom: 0pt">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Address for notice:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">11555 Sorrento Valley Road, Suite 203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">San Diego,
CA 92121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 298.7pt 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 298.7pt 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 298.7pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>7
<FILENAME>aethlon_ex9901.htm
<DESCRIPTION>PRESS RELEASE, DATED SEPTEMBER 4, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="text-align: right; margin: 0">&nbsp;<IMG SRC="aemdlogo.jpg" ALT="" STYLE="height: 62px; width: 180px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">September 4, 2025</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><B>Aethlon Medical Announces Pricing of $4.5 Million
Public Offering</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">SAN DIEGO, Sept. 4, 2025 /PRNewswire/
-- Aethlon Medical, Inc. (&ldquo;Aethlon&rdquo; or the &ldquo;Company&rdquo;) (Nasdaq: AEMD), a medical therapeutic company focused on developing
products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of
5,000,000 shares of its common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 5,000,000 shares of common
stock at a combined public offering price of $0.90 per share (or pre-funded warrant) and accompanying warrant. The warrants will have
an exercise price of $0.90 per share, will be exercisable immediately upon issuance and will expire on the fifth anniversary of the original
issuance date. The closing of the offering is expected to occur on or about September 5, 2025, subject to the satisfaction of customary
closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">Maxim Group LLC is acting as the exclusive
placement agent for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">The gross proceeds from the offering,
before deducting the placement agent&rsquo;s fees and other offering expenses, are expected to be approximately $4.5 million. The Company intends
to use the net proceeds from this offering for general corporate purposes, which may include clinical trial expenses, research and development
expenses, capital expenditures, and working capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">The securities described above are being
offered pursuant to a registration statement on</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">Form S-1, as amended (File No. 333-289745),
which was declared effective by the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on September 4, 2024. The offering is
being made only by means of a prospectus which forms a part of the effective registration statement. A preliminary prospectus relating
to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC&rsquo;s
website at <FONT STYLE="color: #0000EE">www.sec.gov</FONT> and may also be obtained by contacting Maxim Group LLC at 300 Park Avenue,
16th Floor, New York, NY 10022, Attention: Prospectus Department, or by telephone at (212) 895-3745 or by email at <FONT STYLE="color: #0000EE">syndicate@maximgrp.com</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">This press release shall not constitute
an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities
in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><B>About Aethlon Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">Aethlon Medical, Inc. (Nasdaq: AEMD)
is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet
needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic
fluids.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">For more information, visit <FONT STYLE="color: #0000EE">www.AethlonMedical.com</FONT>
and follow the Company on LinkedIn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.2pt 0pt 0; text-indent: -0.5pt">This press release contains
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as &ldquo;may,&rdquo;
&ldquo;believe,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo;
&ldquo;project,&rdquo; &ldquo;will,&rdquo; &ldquo;projections,&rdquo; &ldquo;estimate,&rdquo; &ldquo;potentially&rdquo; or similar
expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and
uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These
forwardlooking statements are based upon Aethlon&rsquo;s current expectations and involve assumptions that may never materialize or
may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company&rsquo;s ability
to raise additional capital on terms favorable to the Company, or at all; the Company&rsquo;s use of net proceeds from the offering;
the Company&rsquo;s ability to successfully complete development of the Hemopurifier; the Company&rsquo;s ability to successfully
demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases, COVID-19 and in the transplant setting;
the Company&rsquo;s ability to achieve and realize the anticipated benefits from operational and financial milestones; the
Company&rsquo;s ability to obtain approval from the Ethics Committee of its third location in Australia, including on the timeline
expected by the Company; the Company&rsquo;s ability to enroll additional patients in its oncology clinical trial in Australia,
including on the timeline expected by the Company; the Company&rsquo;s ability to manage and successfully complete its clinical
trials; the Company&rsquo;s ability to successfully manufacture the Hemopurifier in sufficient quantities for its clinical trials;
unforeseen changes in regulatory requirements; the Company&rsquo;s collaborative research with UCSF Long Covid Clinic; and the
Company&rsquo;s ability to further research potential applications of the Hemopurifier in other EVassociated diseases, the ability
of the Company to maintain its current Patents and other potential risks. The foregoing list of risks and uncertainties is
illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in
forward-looking statements can be found under the caption &ldquo;Risk Factors&rdquo; in the Company&rsquo;s Annual Report on Form
10-K for the year ended March 31, 2025, and in the Company&rsquo;s other filings with the Securities and Exchange Commission,
including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the
date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to
update this information to reflect future events or circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><B>Company Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">Jim Frakes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 223.3pt 0pt 0; text-indent: -0.5pt">Chief Executive Officer and Chief
Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 223.3pt 0pt 0; text-indent: -0.5pt">Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 223.3pt 0pt 0; text-indent: -0.5pt"><FONT STYLE="color: #0000EE">Jfrakes@aethlonmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 223.3pt 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: -0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt">Susan Noonan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0; text-indent: -0.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.5in 0pt 0; text-indent: -0.5pt">S.A. Noonan Communications, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.5in 0pt 0; text-indent: -0.5pt"><FONT STYLE="color: #0000EE">susan@sanoonan.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.5in 0pt 0; text-indent: -0.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="color: black">View original content:</FONT>
<FONT STYLE="color: #0000EE"><U></U>https://www.prnewswire.com/news-releases/aethlon-medicalannounces-pricing-of-4-5-million-public-offering-302546589.html</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="color: #0000EE"><U></U></FONT>SOURCE
Aethlon Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>aemdlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 aemdlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !% ,@# 2(  A$! Q$!_\0
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MQ7D$;'INV8^N 2W!P#BI*/LZBN/\1?%KPIX7\ 0^-+W5HCX>N8([BUNHLO\
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M=>^((X/'6IP?:;323#(6ECVNV=X78.(G/)_AKS?]E+]N;P%^UA)J6F:+!?\
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MW5AX?@?R+<6N%DN9?XB"P("KD=N2<=C7T'_P[\^'/_/_ *[_ .!$7_QNO?O
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MD^*VB?'C3[W0/&&I:F9+3Q;=Z?)/'=P;G+;)%5B%D)$FX<-G!(*@5[+^V_\
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MU)=#\?/VZ?C_ *E^T/\ M&>)-<N1-;Z3I\ITO2;.7(,-K$Q"DCLSDM(?=\=
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M7=)TZ&"YTBV^TSV#P0!)('3.X!F&[(XR!^'M&C>+)=8U2&S.@ZM81RZ>E_\
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M**\G$XB6*JNK+J>GAZ$</25./0?1117*=(4444 %%%% !1110 4444 %%%%
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-*4>6FK(****Q-3__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>aemd-20250904.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +Kopo7xRiXgen8uEbXpMOamBaaPty552aYkxvmR+fWnKDyEqWYy6QCgrS+UmEXoG -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:AEMD="http://aethlonmedical.com/20250904" elementFormDefault="qualified" targetNamespace="http://aethlonmedical.com/20250904">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://aethlonmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20250904_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="aemd-20250904_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>aemd-20250904_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>aemd-20250904_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="aemd-20250904.xsd#Cover" roleURI="http://aethlonmedical.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://aethlonmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P +\# 2(  A$! Q$!_\0
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MAG3/%FCRZ;JD DC891Q]^)NS*>QKYIGM->^#GCR*XV"55SY4A'R74)ZCV/\
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1$-USR*OFDXVF]%Y(-.A__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  04,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Aethlon
Medical, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-3632859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11555
    Sorrento Valley Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite
    203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">941-0360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AEMD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="aemd_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://aethlonmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>aemd-20250904.xsd</File>
    <File>aemd-20250904_lab.xml</File>
    <File>aemd-20250904_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="aemd_8k.htm">aemd_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>20
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "aemd_8k.htm": {
   "nsprefix": "AEMD",
   "nsuri": "http://aethlonmedical.com/20250904",
   "dts": {
    "schema": {
     "local": [
      "aemd-20250904.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "aemd-20250904_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "aemd-20250904_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "aemd_8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://aethlonmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aemd_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "aemd_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://aethlonmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>21
<FILENAME>0001683168-25-006788-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001683168-25-006788-xbrl.zip
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M*$3B_:B(T,SQ@0 _M 82?X=ZX^'1B(1\-*.<NVR."% OK[('8O\#$[M?YRL
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M]SH&L]"= ^F<9E0>.Z"54(<X4Z9B<J 1';CN.CDP**!+]LZKBY-+%8-!#\,
MEJA8(\V#BN#G*=4T__.SJ7G4-7>,7:MO#HEBV1 DEE3+,.C4 6'P_^+A]Y'K
MQ:%'KN8C\MY0+->U)@?DV*#J/9$ K6,9NG:(Y5T7I]@?H6M- YRU)J",2AZ0
MF^W3$G(OQ>0>Y,>RP<KQ F+?!>/0$16VCJ5EJ$'OK_%0&3KNW:BYJ1'#VB9F
M=RZ;VM8#"M"2%9.7E>%)6O.M2_9 -?JD(7.UK<Z#+'_'/'1C\W"J&PQ(!HN<
MSO2]]M65<W/Y4>]O''U)M666AF@QPY=*M;WZ_MYKLO"[1/DTQL(!G?>\DH3*
M1>0I?M[]U6AW[KI[EFELSM"4FE(&$?F65"O5=FOR?J.YBKWPP\ZR&BFL]!+\
ME[+Q7,\P5+0@1+3)'42(#O@>'D-:0XY:C^HEM^^I8O+ZM'>LR41W<)6,H* 3
M,1<_$X6]FS[I3J:&M0#>Q@6'7%KED-1 *"K<G;6^WX$F*@Y_/R_9J+YYV=E;
MZ5S;FF8SQ_%^G>LFD]*MD3$:N)W]?8M);'-KU%BV1BD$@"62&HT&YTO?LB%]
M@*3P#VH8; &,H%J&=2HNE0X:*X8JIP]5,8?MT77/_MIO;#[4W76&*D.:,]-=
MQH<J5VNK4IS7E933-/9UX,\K>V ]FNG,J[HW>Q_H^42A\N;,V\MD7H@>6 ?4
MGNAL9*TM$'MI(^+NX\J^AC /W$1&1*GT[^X;TZ]=\^O&:?$:$>5^YK@31.9;
M'9@_ &[J3X>3&6[DN49+=$R3G+@M2Y&B_32>7UO ".-/?9H=PU\HMK7OO/]V
M]D7=7)":F0R-49!O-65)7EI2^\ZP)\.A>@1@/CJU83+U*34(FS-UYNH/F*:"
M>V7.SKKN/P,+C(S@T'9>R#?_L!6"L-[P[W_MR]+>H0/=##8=6R8C)@^?BACO
M&3,,"7+49A3D10-7#L)9R$IQT*ZTH6NV/$J3X^;-Y9?[FRNZL3S*L<)7%&>^
MM2MEA=T[7 "5UI(Y._:(/[= )*Z1 4_E$W^-:K7CQ^J=LK=Y>5R.%8"2>$&-
MZE*I6MNM_@*U.J5U66F_?&V\< H>!")O4<*RN4.!CU08$9#T(1%U<+ 1Z!ER
M!G7\LO#K%[*VB^ENYD"RL0!G-V;@GW !@$[!>8+9Q(Q/L>9$88;UB$S 1F05
M[G@B0]T W2>Z X; 9:;&M!R$D(X^F1DN-9DU<XP%<2"'<88+_J;W@J4 8NHE
MCKPA4C&< 1Q@O+GPVX:0&EB/^!XZ=!V3..=@2XSX&5.?-7+0T%-YH.MOTM;]
MAG2B&XN#59M]LD*)S[;NPK1B[CPSO5S423=Z$^W;Q<>3CW?]/67CY0S%L@Q&
M3;[=)V$.8R7 5+)P(IM[]?IAIDGT?D6\?<N#!!1&09%I9)'L9@8"49<;GEC&
M%\?XFEA!VB.=TQLBUZIEZ+A#?J$L_8>+ZHDGJGV(IU68$W-T 28+[):14>Q[
M^&#V6=/6/M1?0DYC==5EFC82TA ,R(. LRRA4IV6)#DBI+%EVT!$Z]6RZ/E2
MX>H_0IHBI/[6BFN;H='"W7Q\MP-Z3/MJ.,R*)"_HW5E[QMY/CE]"5F,EZVS2
M-I)9 %=2(_!66EBIKI7D@K*SG@2+OO_(\"O*\%ZZ#/<<9\;LE9)<_WK\P;FL
M-CL?GI<3K2G*C2=$>8G"5Q+H&BO5"^IZ NWU?26!W@!<6CU*H"B!!'(TP0._
MV%7%/1"16$F$^,R&#&J:M@N)J[\7\@.'OB/"WYC:K995\C_5KH,L R+&OVQ#
M5E4N'\>ZRTHX((;G AYM&EG)W7N3GLH.\(",V%VECHD**;236G[S^!)@EW#"
M_/&^">=I@XJKOUY??^$5H8%-<0BDOY@HEE%PLI<:7WZP,!\O.]A+;]\/GU;F
MFSE0:I 2>!)J_O(BYL^PLIU23?=#-L]^+219X<*;[MX:X\[HX^F7Z^;E\[+?
MF!.+K60E\>9;Z-. HWW74N^+Y+=JN5J5R)3:Y($:,T:F>' #]\4_9YGB*=E:
MNP2>PKVZQSU/"80.9%1+U?>FT1Y7S;/-U['DV#I6#&F^A4?=UMW&LBU^#,"%
M)7FRFY H/QK(WF3XX7S_TUWUX[>/SUSB2ZZ%H4*F+8/)^VD2%Z4+-=O1Z+<,
M_I$.G>HNI*,7U+YG[O+ZS4\4P:Q3_NR9N)42*YX+HO)2*+QU#T:,\0TOB3JE
M[A"88(@&$?"(C&SKT1WG("Z<8NV2.D1C0]T4NQY%%:G:6-Y?'=E672,%'.7>
MH2@E^;T!#\S(%#=,8F%:1)>R4I)3@/F3EXMLU@ZA8J@9OAB!6WZ9:NIVI\E@
M0PC1NG%^$Y_?6TMTVK%U5!_=.XZM(Y!EY#AW9O6]O5CL=UZD!)JRQ)I*W-KI
MS<\_XZ%B#E-4S9]Z7(5,U5L]N;20&X-6,@,2#M!*T^+IQ\QAO!>@Y0L8A!^D
MUWE*(DX*X@1Q7,8"D3_J@!HESH0108O-'G0'W@-=IZ:*Q3FJ\J/IV!EO,="H
MK3EBZ4*+Y#ZYV F, @URGVB:6-Y<K@,I^(FG^V<'YP&*',^^IB-V"+V_S; 2
M $ /R=64EP .$*HWH8>XC6J&S?P,-H\D(N>IH[GH;DHNNLM/#X1I8S1-3*:1
M:V8"F?EA(H],[+]%,IZJ/:59Z.5"5*T63V-2>M0S,L;XT7C!]4."Y\0.2-NF
MBJ[ZI^5Q9BZMR'2\YP>T<0(\U!%0%1\6-F?15$O09.NCL1L?" 8Z?I3CG0I-
M3K9B,WI?4AA8$:!RRN5G/0&8QN5EJ48111@=&W*"R]TV[+$"@@3V=F9J*#R6
M?2 R_RVJVA,X()3NN6R"&U"JTJ%4AHRGB[O\<;G9(I3XZRKD!$,M'??UY-HC
MF_$2W9:6RY\F[W56YI^@X0I2PN0)KF+..QQ$8H>#BL Q<3*"1'9IDP(Z'62Q
M7#WT8@C^23K<*1*NACR&Y0R/A)K7,QO\%'C/@.$Q2'YS.!\^4.%!53 F%,\#
MF0_,<2W;B;W=\Y^&E$1KAJ*L@/T[?KB-6#1L<\! 0DB 55\8L*E!&&Z 7-C%
M'&"C\2JD8D!L9F%1&)UUE( K[V% =$'? ?96ZWO%O?TJ\2[8*'B]Q?GZH"\X
M<E5DZX[(UL,T7>3MN2!;3W(_2/'#@1=T0-TH0@R(_Y-':F,LX^!8I_X<S*;X
M,>SDT0>$1&&F(,M]]L#%\ '"9D,N0C>"A>_3&8^,/F=C]GNO@3<%8( [5] ?
M=D"$5XY47G^<U^ *A7BV1_@S@53(B&N-1(Z'LIG#M]/&C3T]//ZS(HF@2HYG
M6VG5<VW"RX?D3R#_%*QW@)9-'"^JS2V;B^(3"DQPDZ%0$'A?!]['YA?";IHR
M0YAI&SJ;(6";6<-B?%X1:"X^?Z2 <1 &;0_,6*"!C*OB)W J@5I#*,63>23;
MMP^$N@3-Z43AJ7[2I$PA\>)# +UO5GF1SM,[A/Q+RL= 3'I4B0C,<X[-F:WJ
M#@]Z]0E>2@7.W5B PD-/-.=X'QQ7P3%]8#P?%&^P-"YSV2D29Z;<P>RB6%$-
M:>.& ,^D,A?S.G<L9$4W?]FY""19-2S,8T$VPX"B(0**,L&>3NC\'X%G60MZ
MT9R;!QA\+[[0>#Q^A9L'^R6)%,1!+*L,D7:M).]#NMH ]R-\^R-U<CRBHP;(
MP!!Z:D*'$P4OE(<@88X<\DIZ.O$X]- F:<]&P!\8GA<S<5!T(HH D?9F,2?:
M8T&'CT=CJD&1 PS8J(J-Y2D1V2\I71=TKD_(.VB:DO/S#J%8=\F!\HEZBVK,
M'.37-'#0=+041<:==S!_.N[9,TVO?!((AB_+99(:%D<=3HZ[?73TB?@@$?'&
MF]5%5KB;V>V)"!9DSN$%8V8Z0E6PU.0P^P%/)H 2H2L%4I1%*J4KF)#E7Z<T
M%1PP!#I!KQ%6TE3JC,F0<:NZ6Y8;;_SJ5-@%YMSA=2T5 /M^/C0G!3KQJV"
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M\30:1S"1^3S+J<U:?_:RV1SFT.T&KATV*_N@()$<]*/"7<!HC'MV!NM-B[.
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M+B/8T&,>("QEL<!/9158"E#CRGQS]T2EHW/X*U<*MU*([SJ;QJ-I@*HC=[3
M&S0=J8T>#Q0/2#2?)^>;#5NM^D9GHH*9 NV4Q!_U-\*VY&L1?RVR'1G34$2H
M#+,%'<I Q,9&SY,;(4QY>:84[P*]@'J)W:Z5;7UN[*@*CDFAAE6C9^B5^.IB
M,1JIHLA TKDC*/7\2A<V;_ZVN@G[IM+NEMS,7W;T4=[&R=SDKOSXGWCB4%[P
M542OWNCM17.XNY+X7[!)>&LO"I$+N#\SE.!GN#^TJ.$;3,[J-#KE,XHK':<G
MA;W46)8X6_2(10G>W)^U>#3;NR;.ZX_XDIVW=>UZ!*D(DO6D<?]JH9Q#+V$9
M(A16?$.5V<WN,%GI.[''GESI'C,[3<L5>OL#F%S^LZYA+^U#-/!<"]CTXTDT
MBY/S%ZL:IV<+.);<5SV>R_V)AB%[)^S"H(AU].O-P/W /2YLFQ9P7\Y!^<$[
M;!P,SWV%91;1;3V+QDJN/KRS\>9/@WF4EUK#W>BQBIN3IEFXNJY[+?G:K*/!
M#A7(%I8X5?T3^S16"=SH>*HS3P*0*C->@$H!NOEH 2/8Z'W>?P/ZY!SOH"&H
M[S(J]1BTH23H0UORSZ@LH]$4!=! S\S'K!2MSO3359RB-(5F6%)"1RJ"K?YE
M5["!1/X:P]3RZU24)S&K.OUX$)1G\+8G [Q,QR!L8=CG;(_T8_P4OI N2!C"
M\]XS(YB'/"YB$8Q')7PIRE%\EF#CD.[[&;9=-B;E6"0]F$$DM$6I' ^P"RS]
M!S#0),G.] M1&&.CUO*!?N%*%5$\9F6:]3&Y-F2=Z(/H! 3\";[ UV_)1( '
M8$(\[3LHYFJ$!J#15E&' HUMF#2N#"SJ68Q[1FL@\%K0R::QU0Z#T52!(C[.
MH[,4-UH4?(%]B-<+6'70XC!*OVWT%FD"J@H;=/!]^L$,>)YG(S5>0#M>]^ST
MC< H4C!E07S1$6S"[^#!;X\S.(BPXT%I:QBF,1ERL!E@O##M::;G&\_ 3(WA
MG]B9DT6$\XFZ.#Q!-WQ0GL_I??8S^ @4@"B/_T5GC#8_OL>T[>B.3K/8V_(,
MMG"!FPPW"'P)-_2)UASD;()1#$N2GS=L#U0\G%?B-^;3\P)-P@3/:YZKFLT$
MDL4_\PLPX!/WW2#+C$P#!0?:J2CQLK^B4SCVM!;&'JRIP/BN(>K)>@/04DX6
M21+2L;&J?\/PF@=0E5D3VJ=@+B0)"[DS+1=R7+FG%3$@8^&3*!V .4&9A'NF
M4685^B#R'+L*=_ 9I#9*8CW HFIOP?(4BZ3$#J"0EXDM6-:"E4Y]YE[AVH".
MZ4BG-::\HF"JR03M-O@N'"*052)YP)XQ&ZWU]=(Y;&"C9UN ;D<IZHNP57Q+
MVSF/JUZ*._[8KK#>*'H5>13:PD:;,\O'( &F)#QY@58W85ZK!2W835,[Y]P#
MOTDM8NGZ([L8UP--8_<,F\T ]A=O+_13]+>]S87/D;$\+TW;*;UA,WCU>J<R
M>M*XR=6FT)Z$'\#$FY>XD^LF>S3ZEF9GB1J?\"U/=BO."GKVX+NYB@JSC5#(
MGL(M1FXV>1,H%_"=:#X-*U>2T5X:]F-UGBM^'[,>M:O'[E,\G:8)1TZP'^\$
MICYE;YYH1G)U1"+O><\5I;;-Z9Q&(WY5-MF\TJ#7I537NZ ^=WVH^.K_U^/'
MP9M8)>,7()]/U$MHXO<%NI2@)\'CQQ)Y?[7_[F]^V/MQF<U?!+_.2]V;Q\.L
M++.9_$Z":OIWKQ,XEL$V=+3(DG@,[5]5B,X)O#58.!>/P]5C<$^?_F37#.-B
M]2>>_=02V')F5\_KR^ 8%*,7P6X>#>/1R^!C-%,\]Z"3P81ONU_Z17\+/VEK
M_6FE=3*N_"YC*$\'\E[] HO9L*Y#D(S?'K,Y] *D(&Z&-=8:1EE'1,Q+=YM[
M+;JCPU'S)OMCGD7L056W)>4&U^ D$T6(;B6K]D<##%^(QQJL8C(5T8U=E.9I
MXWZ&"P;NBA3,KQ&J7NZ#CE^Z7PRL+<Z=<-7@-D<]Z(W9XF0:[!_OD=X?I:SY
M0P-PH\7%%&ZB40(6)[[2";0$<Y7C"_#713R#^R\'13>E 18P.E8W1#TSVN)&
M#WT!%>=Y968<BYV&D9F^D8K!W6OJ$H4^K(XVT#I;GH&5BQI2G!9EOAAQG(A&
MC_>U[EQ(]G!RCF_%U=2Z!1MP!04)_.&P(Q.#-\8F@;Y?LK=@(2R)5 3+ A7:
M?7MJ59@?#$]L].KQB: :GKC-$W<7[M_A'7'C+7'FD<N$_7BHCSM^"53TYVQ/
M73#X"+K]GU 1W=K\;2ML#IFZYE3%SU7OFO%Q=1K=Z,[NJ#WMVO(<^,&["=HV
M)&#(@>OX^MADX4 *WF&I%I\HICAL*S<)V3OD;=317!"58<!^/I3 Z!@K%W!Y
MH'.((]*E>(WHQ67% L.O82#;&I<UVT[$(@M9LN\JMRX::%%29!1NU]X<Z\3>
MZ%6\V"3M:1*&YQ+@)!-3=G[--:ACH<8K5/,'8<."-O'%?<TQL-&347G>"GA]
M&5/0="B3AA=K?!J3BO)?_=W'KP=!_^^#_\;?]W?ASC[#27WQ\([A]M;3S>?S
M<IU>/'ZZC8\^VH$)"?[2=C*\F_O%1J\O?O:_?=W]K.UVUU,2SV9JC"I(<@[[
M&19R7'61KW98Q^)B:?;8];<'&SW0Z*<FE$&.$^O(<Q4"3]N2<TK^[7%TSCJ-
M/E:^OR>G,,,ZK9#;M;49]Z4&?$1NN[G"<#$.3LX-2(0%JI:E?&6:00OZ[/0]
MJ$MPN("9^W5KJS\DK_0A?965O8\?CE"0S!;)"?E6]/T&\D+!O^#0%#8,G41G
M!:&=:+Z=SH8<41&)E\U=WY&6)"HFC:]_WKHC-GI7M25P0?[%[;R.QQ(?L1 )
M>YU+!V"NTU$\A]&:KGR(\F^J1%44;(<LEW#7ZR3+4,:<!.\W/V^ZV!SSB8\E
M,ZJEO@;LE!@-EK>,,V5V<(VAB^4;WFQ 4,YQYM;9+[7-AYO7=7<;=Z<.J='7
M';@:;(!TE"SH!1))\)ZT(<M1DK&7\3(=@[.\\KQB7^(&N7,AB5)S'C>Y@,D
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M ^86UP4V3LG61VVV(:C.N$';W4BZ8Y$BS0,@#+H32SM#>]&$VB1*55?2T86
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M8F28HYHKE\RQ9>AA(X>YH2F1/4AE;AM]87A(O,R0S&=YK<[48$UR#NF'S9-
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MC<)1;AD<\LOK3_O_0#?<+V^//[S?^?]02P,$%     @ 4X$I6]PC#,K@/0
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M53[YLA><PD\-"I9%,HGQF3R+&8#Z#P+:T3\L>!!.!U :_VL%ARU4IV?>[WW
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M"I-1FPC+;L$S!U-0@48AV!WI::$'(U0>@5 9_*(),_V>DZ2W/Y$((+H#492
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ME*_&U<AQ2&G,3 SG+ENDZ6+:J")CZR8,")6K,2,/=>R+#3]0N"@4@SE:1<,
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M6MI>HGYB@-]TW9_([(X@GG#;>Z<#4)><-KU#V256L^]:7"?;)=;[:=)Y>X]
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MWU9G?78ZB\1+9[9YK21)&)%OL;=HW!'=SG5M"5R0?W,[;Z.1N)#EE\[=+AV
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MD2M7Z,<=NXAMZWD0#+^=92G(!O3"IMDK-*N*\,G.84U((^.]QFHC;8^:=>;
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MAE+G./K4%WFDHO2AFB\*Z6/GD1P%[V3=.I+ (21UY4*(M6ML#DX/F2*M/NM
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M*C=$T4_J2Z<4;.&ZJ+ ?"OX>MLAHE"$ZAM(#3%PT##*3)JZNDN/P#,D=JS@
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M@[9AHC&(I2S0P@',TRRR9H>)6 RO-6K>UE\VV=5E0Q8-1MVVDG3+F(\F,.\
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M?PT)9KLB RT[XW\D F3169V^J<'&P0F?6/)4!3:-X6EW4MN'J\(EMEJXQ%W
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M#Y\DL[R[R?,J.<V[J[*NDI_R13'/RC1Y6<U/TB2#%[O.%EDRKYMUW61= =?
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M.:GAITUR6=<+^N@Z*S?9K,SQQRUH+9%;O'^3S_-BS=*>+?+?-ME\BXMW<U6
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MP3EE35F@W*%(B[_Y%J/--%^GEPYK0N[?;3.J<#R=@NED;+;NFM#8-($C:%S
MW2;-N'#I=/*YIN.P S'T23@C1FSTPR*_)WG=[K6#[*=7S<O3>3=B1AF#U%Z-
M!_"#;QX]3E&FP<U!=&'J4(7-IA0#MLDO-V6F\:)ZM2DO"6Q+YP]EE0\+00N1
MK^!I+S$&#2[AR%H4\C5./B8F1B+9>/BO79A,$W8PZ'JY+.9YPVB"=E-VE,:
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M"\I^<)MX*H,I$+/0GV@*C<9GQ',7ZVHX(SN>L]E3<P#5$04Z<VXZJL'-Z63
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M2IJ7,L8N=3@=?U2Q"IQ3PJEQ"2!8A"(@?)K7FX8F^K(&95E1QZ4R="%HHGH
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M,NK3P-B^1><P,8QC,J?D<=&R#4%A<D= 9%4.7>\NOK5[0LT]:8-3FU\\<,A
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M3RJK?-K!832*U2I?X"=D_'74X6Z>%VMI'[AU@4UR2DRS.YN[$E"$N3\:S)9
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M[CAND*^D7?)B"2P_<T(2@)YG]::+]R3Q^LJ]:>K+A)8F;>L+3]/$EJ.:5+O
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M6E!$(=Q,@@@?WU-1T?+M: G_STC;7AB5PCH[S>,_(Y:-+83OBGZB#T$OL^/
M?\>X U;=3PS"Z[@IEXU>!CF O#MF65MP'UA:O[M$*:7^EER4YN2_O^C8F[8(
M,N;]-G21C<211XH;N"?TBUK,,3&=.*1H7X\*KM(HR=&-,=JA+> 9)=$;QD'
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MM>T[%70&.?%M PQM1$$+'LC/EGRBE>!NQT@IGBNMBS(/.K)/HGQE[)GB#Y7
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MT>&3<XPNJ?0-O!Z"PEF(GD?8BS@2B9SQY4#?R=4LFLP<R<@,U7#>LLNUS=&
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MQ['")4Y#R_+'&&<6Y8N2W9YP8S,:^P+?37"WF/@C#FDR1W$E6-"K<"QCXL3
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M]JM,V0A3'L=7;>U2K>9H:!?TR;LETVJ"W(HE5L-4J>K!U1=KU%5-=?%"8';
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M27B</U:G0$WRF?H4AIG__;E_]_\O6FSN%X1/"(0VW/Z)^??3S7>A'R!5'5&
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M%^>]@^IS)!E/@P%GO+!@K?K??,[0[?X2>OIM*_\I@LB(S/OJC(DPS@?'. 8
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M.3 T+GAS9%!+ 0(4 Q0    ( %.!*5M\HT[ _0H  '^&   5
M  "  5P#  !A96UD+3(P,C4P.3 T7VQA8BYX;6Q02P$"% ,4    " !3@2E;
MLR%ZV5X'  #@5P  %0              @ &,#@  865M9"TR,#(U,#DP-%]P
M<F4N>&UL4$L! A0#%     @ 4X$I6R=QHI-'&@  7XL   L
M ( !'18  &%E;61?.&LN:'1M4$L! A0#%     @ 4X$I6TB/2_OM2@  'A "
M !(              ( !C3   &%E=&AL;VY?97@P-# Q+FAT;5!+ 0(4 Q0
M   ( %.!*5O<(PS*X#T  .AK 0 2              "  :I[  !A971H;&]N
M7V5X,#0P,BYH=&U02P$"% ,4    " !3@2E;>.\1I;E*  !$#0( $@
M        @ &ZN0  865T:&QO;E]E># T,#,N:'1M4$L! A0#%     @ 4X$I
M6SON![ORCP  \$P# !(              ( !HP0! &%E=&AL;VY?97@Q,# Q
M+FAT;5!+ 0(4 Q0    ( %.!*5MLK 8CM"H  .'R   2              "
M <64 0!A971H;&]N7V5X,3 P,BYH=&U02P$"% ,4    " !3@2E;X#DP4N,-
M  !B-P  $@              @ &IOP$ 865T:&QO;E]E>#DY,#$N:'1M4$L%
3!@     *  H ?@(  +S- 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>aemd_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="aemd-20250904.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882291</identifier>
        </entity>
        <period>
            <startDate>2025-09-04</startDate>
            <endDate>2025-09-04</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-04" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-04" id="Fact000004">0000882291</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-04" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-04" id="Fact000010">2025-09-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-04" id="Fact000011">Aethlon Medical, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-04" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-04" id="Fact000013">001-37487</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-04" id="Fact000014">13-3632859</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-04" id="Fact000015">11555     Sorrento Valley Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-09-04" id="Fact000016">Suite     203</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-04" id="Fact000017">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-04" id="Fact000018">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-04" id="Fact000019">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-04" id="Fact000020">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-04" id="Fact000021">941-0360</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-04" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-04" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-04" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-04" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-04" id="Fact000026">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-04" id="Fact000027">AEMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-04" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-04" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
